



# Linking epileptic phenotypes and neural extracellular matrix remodeling signatures in mouse models of epilepsy

Armand Blondiaux<sup>a,1</sup>, Shaobo Jia<sup>b,1</sup>, Anil Annamneedi<sup>a,c,d,2</sup>, Gürsel Çalışkan<sup>c,d</sup>, Jana Nebel<sup>a</sup>, Carolina Montenegro-Venegas<sup>a,d,h</sup>, Robert C. Wykes<sup>e,f</sup>, Anna Fejtova<sup>g</sup>, Matthew C. Walker<sup>e</sup>, Oliver Stork<sup>c,d</sup>, Eckart D. Gundelfinger<sup>a,d,h,\*</sup>, Alexander Dityatev<sup>b,d,i,\*</sup>, Constanze I. Seidenbecher<sup>a,d,\*</sup>

<sup>a</sup> Leibniz Institute for Neurobiology (LIN), Magdeburg, Germany

<sup>b</sup> German Center for Neurodegenerative Diseases, Site Magdeburg (DZNE), Magdeburg, Germany

<sup>c</sup> Institute of Biology, Otto-Von-Guericke University, Magdeburg, Germany

<sup>d</sup> Center for Behavioral Brain Sciences (CBBS), Magdeburg 39120, Germany

<sup>e</sup> Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK

<sup>f</sup> Nanomedicine Lab & Geoffrey Jefferson Brain Research Center, University of Manchester, Manchester M13 9PT, UK

<sup>g</sup> Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

<sup>h</sup> Institute for Pharmacology and Toxicology, Otto von Guericke University, Magdeburg, Germany

<sup>i</sup> Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany

## ARTICLE INFO

### Keywords:

Bassoon (*Bsn*) mouse mutants  
Intra-hippocampal kainate model  
Brevican  
Hapln4  
CD44  
*Wisteria floribunda* agglutinin (WFA)

## ABSTRACT

Epilepsies are multifaceted neurological disorders characterized by abnormal brain activity, e.g. caused by imbalanced synaptic excitation and inhibition. The neural extracellular matrix (ECM) is dynamically modulated by physiological and pathophysiological activity and critically involved in controlling the brain's excitability. We used different epilepsy models, i.e. mice lacking the presynaptic scaffolding protein Bassoon at excitatory, inhibitory or all synapse types as genetic models for rapidly generalizing early-onset epilepsy, and intra-hippocampal kainate injection, a model for acquired temporal lobe epilepsy, to study the relationship between epileptic seizures and ECM composition. Electroencephalogram recordings revealed Bassoon deletion at excitatory or inhibitory synapses having diverse effects on epilepsy-related phenotypes. While constitutive *Bsn* mutants and to a lesser extent GABAergic neuron-specific knockouts (*Bsn<sup>Dlx5/6</sup>cKO*) displayed severe epilepsy with more and stronger seizures than kainate-injected animals, mutants lacking Bassoon solely in excitatory forebrain neurons (*Bsn<sup>Emx1</sup>cKO*) showed only mild impairments. By semiquantitative immunoblotting and immunohistochemistry we show model-specific patterns of neural ECM remodeling, and we also demonstrate significant upregulation of the ECM receptor CD44 in null and *Bsn<sup>Dlx5/6</sup>cKO* mutants. ECM-associated WFA-binding chondroitin sulfates were strongly augmented in seizure models. Strikingly, Brevican, Neurocan, Aggrecan and link proteins Hapln1 and Hapln4 levels reliably predicted seizure properties across models, suggesting a link between ECM state and epileptic phenotype.

**Abbreviations:** Acan, Aggrecan; Bcan, Brevican; Bsn/BSN, Bassoon gene; BDNF, Brain-Derived Neurotrophic Factor; ChABC, Chondroitinase ABC; ECM, Extracellular Matrix; HA, Hyaluronic Acid; Hapln1, Hyaluronan And Proteoglycan Link Protein 1; Hapln4, Hyaluronan And Proteoglycan Link Protein 4; Hom, Homogenate; KA, Kainic Acid; KO, Knockout; cKO, Conditional knockout; LVF, Low voltage fast activity; Ncan, Neurocan; Pv, Parvalbumin; PNN, Perineuronal Net; RED, recurrent epileptiform discharges; SW/SW-R, Sharp waves/Sharp wave ripples; Sol, Soluble protein fraction; Syn, Synaptosomal protein fraction; TLE, Temporal Lobe Epilepsy; WFA, *Wisteria Floribunda* Agglutinin; WT, Wild type.

\* Corresponding authors at: Center for Behavioral Brain Sciences (CBBS), Magdeburg 39120, Germany.

E-mail addresses: [gundelfi@lin-magdeburg.de](mailto:gundelfi@lin-magdeburg.de) (E.D. Gundelfinger), [alexander.dityatev@dzne.de](mailto:alexander.dityatev@dzne.de) (A. Dityatev), [cseidenb@lin-magdeburg.de](mailto:cseidenb@lin-magdeburg.de) (C.I. Seidenbecher).

<sup>1</sup> A.B. and S.J. contributed equally to this work.

<sup>2</sup> Current address: Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur-603203, Tamilnadu, India

<https://doi.org/10.1016/j.nbd.2023.106324>

Received 26 May 2023; Received in revised form 11 October 2023; Accepted 11 October 2023

Available online 12 October 2023

0969-9961/© 2023 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

Epilepsy is a pathological brain condition characterized by the propensity to have recurrent seizures. An imbalance of excitation and inhibition has been identified as the underlying cause for epileptic seizure generation (Staley, 2015), but new clinical and genetic findings point to the necessity for a conceptual expansion of this classical paradigm, taking into consideration also other synaptic and extrasynaptic factors determining neuronal homeostasis (Shao et al., 2019). Seizure vulnerability is tightly controlled by manifold synaptic and network mechanisms involving also the perisynaptic extracellular matrix (ECM) and its condensed specialization, the perineuronal nets (PNNs) (Chaunsali et al., 2021; Dzyubenko et al., 2021; Mukhopadhyay et al., 2021; Saghatelian et al., 2001). This ECM is rich in hyaluronic acid (HA), chondroitin sulfate proteoglycans, link proteins, and tenascins and controls tissue properties like volume transmission, as well as stiffness and pH of the extracellular milieu. Neural ECM specializations compartmentalize the extracellular space, e.g. around synapses, and are a major regulator of synaptic plasticity and intrinsic excitability (Dityatev et al., 2010). There is increasing evidence that alterations in various components of the ECM, such as reduced hyaluronan levels, may cause seizures (Arranz et al., 2014; Perkins et al., 2017; Vedunova et al., 2013) or contribute to tissue reorganization during epileptogenesis (Dityatev, 2010; Pitkanen et al., 2014).

The etiology of the epilepsies can be divided into acquired - resulting from structural, immune, infectious, metabolic, or unknown conditions (McWilliam and Al Khalili, 2023) - and genetic, with genetic or presumed genetic causes underlying ~20% of the epilepsies (Balestrini et al., 2021; Dityatev, 2010). Epilepsies frequently result from disrupted synaptic function (Gatto and Broadie, 2010). Accordingly, mutations in genes driving synaptic processes are over-represented in pathways leading to epilepsy (Fukata and Fukata, 2017; Noebels, 2015; do Canto et al., 2021). Among these, molecular processes of presynaptic vesicle cycling and neurotransmitter release frequently result in epilepsy (John et al., 2021; Verhage and Sorensen, 2020).

One of the synaptic proteins implicated in epileptogenic pathways is Bassoon, a presynaptic scaffolding protein that is involved in the assembly and molecular organization of the apparatus for neurotransmitter release in excitatory and inhibitory presynapses (Gundelfinger and Fejtova, 2012; Gundelfinger et al., 2016). Mutations in the murine *Bsn* gene, which result in deletions of large parts of the protein (*Bsn*<sup>ΔEx4/5</sup>), cause massive sensory impairment (Dick et al., 2003; Khimich et al., 2005; Tom Dieck et al., 2005) and severe, rapidly generalizing seizures (Altrock et al., 2003). Epilepsy in these animals is associated with prolonged brain growth and increased levels of brain-derived neurotrophic factor (BDNF) in the forebrain (Angenstein et al., 2007, 2008; Heyden et al., 2011; Dieni et al., 2012), and abnormal synaptic function and plasticity in the hippocampus and the striatum (Altrock et al., 2003; Ghiglieri et al., 2009, 2010; Sgobio et al., 2010). The epilepsy can be ameliorated by long-term treatment with the anticonvulsant valproic acid (Ghiglieri et al., 2010; Sgobio et al., 2010) and by rearing mutant mice in enriched environment (Morelli et al., 2014). In humans, manifold evidence has been reported that mutations in the *BSN* gene are linked to brain dysfunctions associated with epilepsies. These include intellectual disability (Froukh, 2017), sudden infanticide (Brohus et al., 2021), the Landau-Kleffner syndrome, a rare childhood epileptic encephalopathy (Conroy et al., 2014), and febrile seizures (Skotte et al., 2022). Another very recent study identified multiple variants of the *BSN* gene – both truncations and compound heterozygous mutations – associated with early developmental seizures, thus placing *BSN* among the potential human epilepsy genes (Ye et al., 2022). However, the underlying molecular mechanism of Bassoon causing these syndromes is still unclear, as is the synapse type-specific contribution of Bassoon deficiency.

For studying seizure generation and epileptogenesis, various animal models have been developed (Kandratavicius et al., 2014), among which

systemic or intrahippocampal injection of the chemoconvulsant kainate (KA) is frequently used as a model for acquired temporal lobe epilepsy (TLE, Rusina et al., 2021). Unilateral intrahippocampal KA injection produces recurrent seizures, usually evokes unilateral hippocampal sclerosis and reproduces human TLE pathology (Bouillere et al., 1999; Grötcke et al., 2008; Jefferys et al., 2016). Thus, in our study we used this model for comparison and as reference for our genetic models.

To further elucidate the significance of Bassoon mutations and the contribution of the neural ECM in epileptic phenotypes, here, we address the following questions: (i) What role does absence of Bassoon from excitatory and inhibitory synapses play in the development of epilepsy in mice? (ii) How does Bassoon-dependent epilepsy compare to the intrahippocampal KA model of TLE? (iii) How do the different types of epilepsy affect the composition of the neural hyaluronan-based ECM and, more generally, the distribution and proteolytic processing of ECM molecules or the hyaluronan receptor CD44 in different epilepsy-relevant brain subregions and subcellular protein fractions/compartments?

## 2. Material and methods

### 2.1. Mouse models

Mice were housed under standard conditions on a 12-12 h light-dark cycle. Food and water were provided ad libitum. All *Bassoon* mutant lines were bred in a C57BL/6 N genetic background at the LIN. Three lines (*Bsn*<sup>ΔEx4/5</sup>, *Bsn*<sup>gt</sup>, *Bsn*<sup>KO</sup>) are constitutive and affect the *Bsn* gene in all cells. In *Bsn*<sup>lx/lx</sup> the *Bsn* gene is floxed; *Bsn*<sup>Emx1</sup> and *Bsn*<sup>Dlx5/6</sup> are conditional knockouts (cKOs) with functional inactivation of the *Bsn* gene in the glutamatergic forebrain and GABAergic interneurons, respectively (for details see Supplementary Fig. S1; Altrock et al., 2003; Annamneedi et al., 2018; Hallermann et al., 2010; Schattling et al., 2019). The animals used for the KA experiments had the C57BL/6 J background and were bred under similar specific pathogen-free conditions at the DZNE. Animal breeding and experiments were carried out in accordance with the European Communities Council Directive (2010/63/EU, amendment 2019) and approved by the authorities of the State Saxony-Anhalt (Landesverwaltungsamt Halle) to LIN (TVA No.: 42502–2-1484 LIN) and DZNE (TVA No.: 42502–2-1316 DZNE).

### 2.2. Antibodies, enzymes and drugs

The following antisera/antibodies were used: guinea pig anti-Brevican (diluted 1:1000 for Western blots [WB] and 1:500 for immunohistochemistry [IHC]) and rabbit anti-Brevican (1:1000 for WB) (Seidenbecher et al., 1995; John et al., 2006); rabbit anti-Aggrican (Millipore, AB1031, 1:500 for WB; RRID:AB\_90460); sheep anti-Neurocan (R&D Systems, AF5800; 1:200 for WB; RRID:AB\_2149717); goat anti-Tenascin-R (Santa-Cruz, sc-9875; 1:200 for WB; RRID:AB\_2207007); rabbit anti-Tenascin-C (Cell Signaling Tech, #12221; 1:1000 for WB; RRID:AB\_2797849); goat anti-Hapln1 (R&D Systems, AF2608, 1:200 for WB; RRID:AB\_2116135); goat anti-Hapln4 (R&D Systems, AF4085; 1:200 for WB; RRID:AB\_2116264); rabbit anti-GFAP (Synaptic Systems, 173,002; 1:500 for IHC; RRID:AB\_887720); sheep anti-CD44 (R&D Systems, AF6127; 1:500 for WB and 1:100 for IHC; RRID:AB\_10992919); *Wisteria floribunda* Agglutinin (WFA; VectorLab; 1:250 for lectin histochemistry or B1355 biotinylated-WFA antibody, VectorLab 1:500).

Fluorescently labeled secondary antibodies for WB were purchased from Invitrogen (Alexa Fluor 680 & 790, dilution 1:15,000) while antibodies for IHC were obtained from Dianova (Cy3 & Cy5, dilution 1:500). Secondary antibodies coupled to peroxidase (POD) were from Jackson Immuno Research (dilution 1:5000). Streptavidin was purchased from Invitrogen (Alexa Fluor 488 conjugated, S11223, 1:1000). Fluoromount-G (Invitrogen) containing DAPI was used for mounting IHC stained slices. Kainic acid (KA; K0250-10MG) and Chondroitinase

ABC (ChABC; C3667) were purchased from Sigma-Aldrich.

### 2.3. Recording of seizure activity

Recordings were done in mature adult 4–7 months-old Bsn mutant and control mice and for 6–8 months-old KA-injected mice. The timeline of the experimental design as well as the age ranges for all mouse groups are indicated in Supplementary Fig. S2. EEG recordings were sampled during the 1st week (KA<sup>1wk</sup>) or the 4th week (KA<sup>4wk</sup>) after KA injection.

#### 2.3.1. Surgery and kainate injection

Implantation of electrodes for electroencephalographic (EEG) recordings (electrode E363/96/1.6/Spc, Bilaney consultants GmbH) and cannula placement for kainic acid injection were performed as described previously (Broekaart et al., 2021). After surgery a 3D-printed cap (polylactic acid) composed of two chambers, one for the wireless transmitter and one for the battery, was mounted and the transmitter was attached to the electrode.

For the intrahippocampal kainate model, KA was administered to the CA1 region of the right hippocampus (10 mM, 120 nl at 3 nl/s) (Broekaart et al., 2021). Sham-operated control animals were injected with physiological saline accordingly.

#### 2.3.2. EEG recording and analysis

For recording and analysis experimenters were blinded for genotypes and pharmacological treatment. After a recovery period of about 7–12 days in individual cages, wireless recordings of freely moving animals were performed utilizing the LWDAQ+ software (Open Source Instruments) for up to 10 days, out of which 4–5 consecutive days were sampled (Supplementary Fig. S2). With the LWDAQ Neuroarchiver Tool recordings were cut into 4 s frames with a glitch threshold at 200 counts to remove artefacts. In each of the 4 s-frames, the ECP19 processor extracted 6 properties from the EEG trace (for details see: Hashemi, 2008–2022, <https://www.opensourceinstruments.com/Electronics/A3018/Neuroarchiver.html#Interval%20Processing>). The software stored the properties of a selected set of traces collected outside of the actual recording periods for comparison in a library. For Bsn mutants, a library of 143 ictal intervals was compiled to be used as references by the software. The library for the KA animals was compiled similarly from their own recordings, with 171 events for one week (KA<sup>1wk</sup>) and 287 events for the four weeks (KA<sup>4wk</sup>) post-KA injection recordings.

The library is then used to classify the remaining recordings. The software computes a space based on the 6 ECP19 processor properties and places each 4 s frame in this space before comparing their distance with the closest trace of the library. A 4 s frame was considered ictal if the distance to a library point was below an 0.1 threshold distance. It was then confirmed manually whether or not the frames identified as ictal during this process were or not part of an actual seizure. Ictal-like events with a duration below 8 s were not considered as seizures. Moreover, the precision of the library was tested against two animals fully reviewed by eye, for each library. We took one animal without seizures to make sure that it was not a false negative and one animal with seizures to make sure that all possible seizures were properly detected by the library. The library was considered accurate once all seizures from the second animal could be selected and it was confirmed that the animal without any detected seizures indeed had none.

Seizure onset patterns can fall into different categories (Perucca et al., 2014). To classify seizure onset types, two observers independently inspected the onset of each seizure and classified them according to pre-ictal and ictal high frequency oscillation analysis. They then compared their classifications and reached consensus. As most seizure onsets fall into the low-voltage fast activity (LVF) group (see results) further events including hypersynchronous and undefined onset types were grouped as ‘others’. Only animals with at least three seizures observed were used for quantification of the fraction of LVF seizures.

### 2.4. Slice electrophysiology

#### 2.4.1. Slice preparation

Slice preparation and extracellular field recordings were performed similar to our previous studies (Caliskan et al., 2015, 2016). Young adult mice (10 to 25 weeks old) were decapitated under deep isoflurane anaesthesia and brains were extracted. Horizontal ~400 µm thick brain slices were cut using an angled platform (12° in the fronto-occipital direction) in ice-cold, carbogenated (5% CO<sub>2</sub> / 95% O<sub>2</sub>) artificial cerebrospinal fluid (aCSF) containing (in mM) 129 NaCl, 21 NaHCO<sub>3</sub>, 3 KCl, 1.6 CaCl<sub>2</sub>, 1.8 MgCl<sub>2</sub>, 1.25 NaH<sub>2</sub>PO<sub>4</sub> and 10 glucose (pH 7.4, ~300 mOsm/kg) with a vibrating microtome (Campden Instruments; Model 752) and quickly transferred to an interface chamber perfused with aCSF at 32 ± 0.5 °C (flow rate: 2.0 ± 0.2 ml/min). The slices were cut until three-to-four slices containing transverse sections of ventral-to-mid hippocampus were obtained. Slices were incubated at least for an hour before recordings were started. Recordings were performed blinded for the experimenter.

#### 2.4.2. Sharp wave-ripples and recurrent epileptiform discharges

Analog field potential (FP) signals were pre-amplified and low-pass filtered at 3 kHz using a custom-made amplifier. Then, the analog FP signal was digitized at 5 kHz using an analog-to-digital converter (Cambridge Electronic Design, Cambridge, UK) and stored on a computer hard disc for further signal processing and data analysis as previously described (Caliskan et al., 2016). Sharp wave-ripple (SW-R) recordings were obtained with borosilicate glass electrodes filled with aCSF (resistance in aCSF: 1 MΩ) placed at the pyramidal layer of CA3 and CA1 subregions. Three-to-five min data were recorded, and 2 min artifact-free data were extracted as MATLAB files. Custom written MATLAB-scripts were used to analyze distinct properties of SW-R (MathWorks, Natick, MA). SW detection was performed by using the low-pass filtered at 45 Hz (Butterworth, 8th order) with a detection threshold of 2.5 times the standard deviation (SD) of the lowpass-filtered signal and a minimum interval of 80 ms between two subsequent SW. SW events were stored as 125 ms data stretches centered to the maximum of SW. The mean of the data was used to determine the start and the end point of SW. The area of SW was calculated via integrating the area under curve of low-pass-filtered data between the start and end of the SW event. Ripples were detected using band-pass filter at 120–300 Hz (Butterworth, 8th order) and a detection threshold of 3 SD of the band-pass filtered data. Data stretches of 25 ms (15 ms before and 10 ms after the maximum of SW event) were isolated for further analysis. Triple-point-minimax-determination was used to analyze ripple amplitudes. Ripples with higher than 75% amplitude difference between falling and rising component were discarded. Ripple frequencies were calculated using the time interval between two subsequent ripples.

#### 2.4.3. Statistical analysis of electrophysiological data

SigmaPlot for Windows Version 11.0 (Systat software) was used for statistical analysis of in vitro electrophysiological data. Normality test (Shapiro-Wilk Test) and equal variance test were performed before commencing other statistical tests. For hippocampal network oscillations, statistical differences were determined by Student's two-tailed *t*-test or Mann-Whitney *U* test. To determine whether probability to induce recurrent epileptiform discharges was altered, the Fisher's exact test was used. Probability values of *P* < 0.05 were considered as statistically significant. Sample sizes are provided in figure captions (*N*: Number of mice; *n*: Number of slices).

### 2.5. Protein biochemistry and immunoblot analysis

After EEG recording animals were euthanized with carbon dioxide. Brains were removed, frozen in liquid nitrogen and stored at –80 °C until further use. Brains were thawed in PBS, homogenized and fractionated essentially as described (Carlin et al., 1980; Tom Dieck et al.,

1998). The following fractions were collected and probed for the presence of ECM components: homogenate (S1), i.e. raw lysate after removing nuclei and cell debris by 1000 ×g centrifugation; soluble fraction (S2), i.e. supernatant after 13,000 ×g centrifugation of S1 containing mainly cytosolic and extracellular soluble components; and synaptosomes, enriched for synaptic and perisynaptic proteins (Carlin et al., 1980; Tom Dieck et al., 1998). To remove chondroitin sulfate side chains from core proteins of proteoglycans fractions were digested with ChABC in a 1:400 dilution of a 0.1 U/μl solution for 90 min at 37 °C (Seidenbecher et al., 1995) and subjected to semiquantitative immunoblot analyses.

Protein samples (6–20 μg/lane) were separated by SDS-PAGE on 2.5–10% or 5–20% gradient gels and 2,2,2-trichloroethanol in-gel staining was used for loading control. Proteins were transferred onto PVDF membranes (Immobilon-FL, 0.45 μm pore size, Millipore) following standard procedures. Immunoblots were developed with specific primary antibodies followed by incubation with peroxidase-coupled secondary or fluorescent secondary antibodies. Peroxidase-labeled membranes were developed with an ECL Chemocam Imager (INTAS Science Imaging Instruments GmbH) the fluorescently labeled blots were scanned with an Odyssey scanner (LI-COR® Biosciences). The quantification was done with ImageJ (<https://imagej.nih.gov/ij/>) and values were normalized to samples from respective control animals.

## 2.6. Immunohistochemistry

For immunohistochemistry animals were euthanized with carbon dioxide and after death quickly perfused using a peristaltic pump. Brains were removed and processed essentially as described earlier (Annamneedi et al., 2018). Before any analysis, the negative control sections (without primary antibody incubations) were checked for the absence of fluorescence signal under a fluorescence microscope (Zeiss, Axioplan 2). In case there was a signal, the corresponding channel was disregarded for qualitative and quantitative analysis.

Stained brain slices were observed under a confocal microscope (TCS SP5, Leica Microsystems). Images were taken at 1024 × 1024 px resolution with 15% overlap to ensure proper image stitching over a Z-stack of 17 images 0.59 μm apart (9.399 μm in total). Images were stitched together using Mosaic-Merge function in LAS X software (Leica Microsystems) and analyzed utilizing the FIJI program package (Schindelin et al., 2012).

## 2.7. Further statistical analyses

### 2.7.1. Survival analysis

Animals were genotyped after weaning, i.e. about 3 weeks postnatally. A survival analysis was conducted with the data of the five *Bsn* mutant lines and a group of control animals including WT and *Bsn*<sup>lx/lx</sup> animals from the LIN records. It comprised the records of all the animals genotyped between January 1, 2017 to August 1, 2020. The Kaplan-Meier plot and the Cox proportional hazard models are fitted with “spontaneous deaths” only considered as the event. Any other type of death due to experimental use led to a censored data point at the appropriate time. Events before weaning were not counted. In order to estimate the number of animals lost before genotyping, the number of animals of each genotype was determined and compared to the expected Mendelian numbers of the corresponding breedings.

### 2.7.2. Statistical analysis of ECM expression and correlation

Unless otherwise stated, the statistical analysis was conducted with the R statistical software (<https://www.rproject.org/>), using the following packages: broom, car, corrplot, dplyr, edfReader, emmeans, ggfortify, glmnet, ggplot2, reshape2, plyr, psych, scales, survminer, tidy.

Analysis of covariance (ANCOVA), and linear multivariate discriminant and regression analyses were performed using XLSTAT (version

2020.5.1, Addinsoft). Corrected  $R^2$ , which corresponds to the fraction of the dependent variable variance that is explained by the linear model, was used as a standard measure to report the regression quality. For regression analysis, minimal set of best predictors was selected, which corresponded to the local maximum of corrected  $R^2$  and all significant predictors are reported in Fig. 5B.

Several statistical tests, reported along with the corresponding *p*-value, were used for group comparison. Post-hoc tests were carried out in cases when the analysis of variance (ANOVA) revealed significant effects of factors or their interactions, with personalized contrasts on least-square means. Following the post-hoc tests, the *P*-values were corrected for multiple comparisons. The statistical tests were considered significant if *P* < 0.05. For multiple testing, the *P*-value was adjusted with the false discovery rate method (fdr).

## 3. Results


### 3.1. Bassoon mutant mice as an early-onset epilepsy model

The first mouse mutant generated for the *Bsn* gene, *Bsn*<sup>ΔEx4/5</sup>, had a shorter life expectancy due to epileptic seizures in the homozygotes (Altrock et al., 2003). As this mutant still expressed parts of the Bassoon protein, it was not clear, whether the seizures were due to loss of Bassoon function in the CNS or due to gain of function due to the residual 180-kD protein fragment. To assess Bassoon function in the mammalian brain in more depth, additional constitutive and conditional mutants were generated (Supplementary Fig. S1). These include a gene trap line, *Bsn*<sup>gt</sup> (Hallermann et al., 2010) and a conditional line, in which the second protein-coding exon of the *Bsn* gene was flanked by loxP sites (*Bsn*<sup>lx/lx</sup>) and which does not show any overt phenotype (Annamneedi et al., 2018). *Bsn*<sup>lx/lx</sup> mice were used to generate constitutive null mutant mice upon somatic cre-recombination and germline transmission of the *Bsn* gene (*Bsn*<sup>KO</sup>; Schattling et al., 2019) as well as to produce conditional knockouts for Bassoon in glutamatergic forebrain neurons (*Bsn*<sup>Emx1</sup> cKO; Annamneedi et al., 2018) and in a distinct subset of GABAergic inhibitory neurons of the murine brain (*Bsn*<sup>Dlx5/6</sup> cKO; Supplementary Fig. S1).

First, we examined survival rates and seizure frequencies of the different mutants. To this end, genotype frequencies of about 3 weeks-old mice, i.e. after weaning, were determined (Fig. 1A). With the exception of *Bsn*<sup>Dlx5/6</sup>, all lines have significantly lower numbers of homozygous mutants than expected as compared to wild-type or *Bsn*<sup>lx/lx</sup> control mice. Currently it is unclear whether this is entirely due to pre- or early postnatal lethality or if, and to which extent, reduced fertility of mutant germ cells contributes to this imbalance of Mendelian ratios. To further assess lethality of the *Bsn* mutation, we monitored survival over the course of 6 months after genotyping by applying Kaplan-Meier estimation (Fig. 1B). From the constitutive mutant lines (*Bsn*<sup>ΔEx4/5</sup>, *Bsn*<sup>gt</sup>, *Bsn*<sup>KO</sup>) about 50% of homozygous animals died spontaneously during this period, most of them displaying the typical posture of animals that have died from epileptic seizures. This is consistent with the survival rate initially observed for *Bsn*<sup>ΔEx4/5</sup> (Altrock et al., 2003). *Bsn*<sup>Dlx5/6</sup> cKO animals had a survival rate of about 70%. We quantified the increased risk of spontaneous death in these lines using a Cox proportional hazard model with the non-mutant littermates as reference (likelihood ratio test (6 d.f.) = 467.5, *P* < 2.00 × 10<sup>−16</sup>). It shows no difference in survival between sexes over all mouse lines studied (coeff = −0.04, *p* = 0.76, female as reference). The *Bsn*<sup>Emx1</sup> line shows no decrease in survival (coeff = −0.05, *P* = 0.92) as compared to all other *Bsn* lines. We noted an 11-fold increased risk of spontaneous death for *Bsn*<sup>Dlx5/6</sup> (coeff = 2.43, *P* < 2.00 × 10<sup>−16</sup>), 14.5-fold for *Bsn*<sup>KO</sup> (coeff = 2.68, *P* < 2.00 × 10<sup>−16</sup>), 17.4-fold for *Bsn*<sup>gt</sup> (coeff = 2.86, *P* < 2.00 × 10<sup>−16</sup>) and 20-fold increase in spontaneous death risk in the *Bsn*<sup>ΔEx4/5</sup> line (coeff = 3.02, *P* < 2.00 × 10<sup>−16</sup>).

Long-term EEG recording of a sample of mice revealed that 100% of constitutive mutant mice and of GABAergic cKOs experienced epileptic





**Fig. 1.** Survival rates and seizure frequencies of Bassoon mutant mice.

(A) Genotype frequencies of Bassoon-mutant animals after weaning (3 weeks-old) as compared to expected Mendelian ratios. With the exception of *Bsn*<sup>Dlx5/6</sup>, all the lines have lower numbers of homozygous mutants than expected. Chi-squared test was used to assess statistical significance. (B) Kaplan-Meier survival curve for spontaneous death in genotyped Bassoon mutants. Animal numbers included in the analysis were: *Bsn* <sup>$\Delta$ Ex4/5</sup>  $n = 52$ ; *Bsn*<sup>gt</sup>  $n = 287$ ; *Bsn*<sup>KO</sup>  $n = 172$ ; *Bsn*<sup>Dlx5/6</sup>  $n = 88$ ; *Bsn*<sup>Emx1</sup>  $n = 210$ ; WT/*Bsn*<sup>Lx/Lx</sup> as controls  $n = 2154$ . No sex differences in the survival were observed in the Cox model ( $P = 0.76$ ). (C) Rate of animals of Bassoon mutant lines developing electrographic seizures during an observation period of 6–10 days ( $n = 4$ –5 per mutant group,  $n = 26$  for control animals). Color code in panel B is the same as in (C).

seizures while only 2 out of 5 of the glutamatergic cKOs displayed seizure activity. Control littermate mice only very rarely suffered from seizures (1 of 26; Fig. 1C). Thus, as already observed for the *Bsn* <sup>$\Delta$ Ex4/5</sup> mouse line (Ghiglieri et al., 2009), also the *Bsn*<sup>gt</sup>, *Bsn*<sup>KO</sup> and *Bsn*<sup>Dlx5/6</sup> cKO mice may be considered as early-onset epilepsy models, whereas *Bsn*<sup>Emx1</sup> cKO suffer from mild epilepsy. However, as the age of the mice at the start of EEG measurements varied between 15 and 27 weeks for *Bsn*<sup>gt</sup>, *Bsn* <sup>$\Delta$ Ex4/5</sup>, *Bsn*<sup>KO</sup> and *Bsn*<sup>Dlx5/6</sup> and 30–31 weeks for *Bsn*<sup>Emx1</sup> cKO (see age table in Supplementary Fig. S2C) we cannot definitely rule out an age effect.

### 3.2. Seizure frequencies and types in *Bsn* mutant vs. intrahippocampal kainic acid-injected mice


Next, we assessed frequency and severity of seizures in *Bsn* mutants and compared them to an established mouse model of TLE following the unilateral injection of kainic acid into the hippocampus (intrahippocampal KA mouse model; Broekaart et al., 2021). Examples of telemetric EEG recordings of the various mouse models are given in Fig. 2A. Seizure frequencies varied from several events per day to one event about every three days. The highest seizure rate with more than four ( $4.19 \pm 0.59$ ) events per day was observed for the *Bsn*<sup>KO</sup> mice. The other constitutive *Bsn* mutants have a trend-wise lower seizure rate (two-way ANOVA on rankings,  $F_{(6, 76)} = 4.477$ ,  $P = 0.006$ , post-hoc Holm-Sidak method), which is between 1 and 2 for *Bsn*<sup>gt</sup> ( $2.12 \pm 0.45$ ,  $P = 0.949$ ), *Bsn* <sup>$\Delta$ Ex4/5</sup> ( $1.09 \pm 0.52$ ,  $P = 0.520$ ) and *Bsn*<sup>Dlx5/6</sup> ( $1.18 \pm 0.39$ ,  $P < 0.515$ ). Mice lacking Bassoon in a subset of inhibitory neurons experienced on average more than one seizure event daily. In contrast, the *Bsn*<sup>Emx1</sup> cKO line lacking Bassoon expression in excitatory forebrain neurons displays significantly lower seizure rates; here, only two out of 5 mice tested have epileptic seizure rates of 0.5–1 daily (Fig. 2B). Seizure

rates differ significantly, with all other *Bsn* mutants showing markedly higher rates than the *Bsn*<sup>Emx1</sup> mice (*Bsn*<sup>KO</sup>,  $P < 0.0001$ ; *Bsn*<sup>gt</sup>,  $P = 0.003$ ; *Bsn*<sup>Dlx5/6</sup>,  $P = 0.023$ ; *Bsn* <sup>$\Delta$ Ex4/5</sup>,  $P = 0.049$ ).

For comparison, we examined mice of the intrahippocampal KA model one week (KA<sup>1wk</sup>) and four weeks (KA<sup>4wk</sup>) after unilateral kainate injection. Here, seizure activity was observed in 5 of 12 animals of the KA<sup>1wk</sup> group ( $0.55 \pm 0.25$  / day) and in 5 of 9 mice of the KA<sup>4wk</sup> group ( $0.37 \pm 0.16$  / day) during the observation period of 5 consecutive days (Supplementary Fig. S2). As shown in Fig. 2B, KA<sup>1wk</sup> mice presented significantly lower seizure frequency than *Bsn*<sup>KO</sup>, *Bsn*<sup>gt</sup>, *Bsn*<sup>Dlx5/6</sup> and *Bsn* <sup>$\Delta$ Ex4/5</sup> mice ( $P < 0.0001$ ,  $P = 0.0011$ ,  $P = 0.012$ ,  $P = 0.040$ , respectively), and KA<sup>4wk</sup> mice presented significantly lower seizure frequency than *Bsn*<sup>KO</sup>, *Bsn*<sup>gt</sup> and *Bsn*<sup>Dlx5/6</sup> mice ( $P < 0.0001$ ;  $P = 0.006$ ;  $P = 0.045$ , respectively). No seizures were detected in control mice for the intrahippocampal KA model (except for one mouse), which underwent similar surgery but received physiological saline injection.

The evaluation of averaged seizure duration in *Bsn* mutant mice and KA mice is presented in Fig. 2C. Two-way ANOVA on rankings revealed significant difference between animal lines ( $F_{(6, 76)} = 3.601$ ,  $P = 0.0034$ , post-hoc Holm-Sidak method). *Bsn*<sup>KO</sup> mice showed the longest seizure duration ( $43.2 \pm 7.4$  s), significantly longer than *Bsn*<sup>Emx1</sup> mice ( $18.9 \pm 11.9$  s,  $P = 0.009$ ), KA<sup>1wk</sup> mice ( $9.3 \pm 3.4$  s,  $P < 0.0001$ ) and KA<sup>4wk</sup> mice ( $24.3 \pm 9.2$  s,  $P = 0.019$ ). Also, KA<sup>1wk</sup> mice were different from three *Bsn* mutant lines (*Bsn* <sup>$\Delta$ Ex4/5</sup>,  $43.2 \pm 7.4$  s,  $P = 0.0012$ ; *Bsn*<sup>gt</sup>,  $31.9 \pm 3.4$  s,  $P = 0.015$ ; *Bsn*<sup>Dlx5/6</sup>,  $35.0 \pm 4.9$  s,  $P = 0.002$ ).

Assessment of seizure onset types (Fig. 2A, D) revealed that in particular *Bsn*<sup>KO</sup> and *Bsn*<sup>Dlx5/6</sup> lines display a high proportion of low-voltage fast activity (LVF) onset signatures ( $84 \pm 6\%$  and  $75 \pm 17\%$ , respectively). Mechanistically, LVF onset signatures are thought to rely on the inhibitory circuits to trigger seizure activity (Elahian et al., 2018). Mixed onset types were observed for other *Bsn* mutants as well as for



**Fig. 2.** Characterization of seizures in *Bsn* mutant mice as compared to KA-injected animals.


(A) Examples of EEG recordings from control animals (*Bsn*<sup>lx/lx</sup>) and each of the *Bsn* mutant lines as well as from intrahippocampally kainate-injected animals, a model of mesial TLE. For each line, a typical example of an epileptic seizure and a zoom on the onset signature is presented. (B) Plot of the average seizure frequency in all *Bsn*-mutant lines and kainate-injected animals both 1 week and 4 weeks post-injection. Time periods for seizure recordings for the different experimental groups are provided in Supplementary Fig. S2C. (C) Plot of the average seizure duration in all *Bsn*-mutant lines and kainate-injected animals both 1 week and 4 weeks post-injection. (D) Proportion of low-voltage fast (LVF) onsets (color shades, color code as in Fig. 1C) over all observed seizures in the different epileptic lines (total events per mouse group: *Bsn*<sup>ΔEx4/5</sup> *n* = 22; *Bsn*<sup>gt</sup> *n* = 49; *Bsn*<sup>KO</sup> *n* = 109; *Bsn*<sup>Dlx5/6</sup> *n* = 74; *Bsn*<sup>Emx1</sup> *n* = 16; KA<sup>1wk</sup> *n* = 26; KA<sup>4wk</sup> *n* = 17). In panel B and C data are presented as mean ± SEM. Statistics: Two-way ANOVA performed using the rank-transformation of data values; post-hoc test: Holm-Sidak methods. \* *P* < 0.05; \*\* *P* < 0.01; \*\*\* *P* < 0.001.

KA<sup>1wk</sup>, whereas in KA<sup>4wk</sup> animals, other onset types including hyper-synchronous onset seizures prevailed (Fig. 2A, C).

### 3.3. Spontaneous recurrent epileptiform discharges in entorhinal-hippocampal slices of *Bsn*-mutant mice

The Bassoon-mutant line *Bsn*<sup>ΔEx4/5</sup> has been characterized by the occurrence of interictal spikes in the cortex and hippocampus (Altrock et al., 2003). The appearance of hippocampal sharp waves (SW) and the co-occurrence of spontaneous recurrent epileptiform discharges (REDs) can provide hints to epileptic events as already minor changes in

hippocampal circuitry (e.g., inhibitory tonus) can transform SW-Rs into pathological epileptiform activity (Behrens et al., 2007; Buzsaki, 2015; Cheah et al., 2021; Karlocai et al., 2014; Liotta et al., 2011). Therefore, to gain deeper insight into potential seizure-generating mechanisms in *Bsn* mutants, we investigated three mutant lines derived from mice with the floxed *Bsn* gene, i.e. *Bsn*<sup>KO</sup>, *Bsn*<sup>Emx1</sup> and *Bsn*<sup>Dlx5/6</sup> for the occurrence of spontaneous REDs as well as for SWs in the hippocampus (Fig. 3). In *Bsn*<sup>KO</sup> mice, about one quarter (26.0%) of entorhinal-hippocampal slices (7 out of 27 slices; 3 out of 5 mice) showed spontaneous REDs, while no such events were observed in control *Bsn*<sup>lx/lx</sup> mice (Fig. 3A, B). The SW incidence was similar in CA3 (*t*<sub>(41)</sub> = −0.0816, *P* = 0.935), but



**Fig. 3.** Spontaneous recurrent epileptiform discharges (REDs) and sharp wave (SW) incidences in entorhinal-hippocampal slices of *Bsn*-mutant mice.

(A) Representative field potential traces illustrating reduced sharp wave (SW) incidence in hippocampal CA1 of *Bsn*<sup>KO</sup> mice. Note the co-presence of spontaneous REDs in slices from *Bsn*<sup>KO</sup> mice. (B) About 25% of entorhinal-hippocampal slices of *Bsn*<sup>KO</sup> mice (7 out of 27 slices; 3 out of 5 mice) exhibited REDs in addition to SW while no REDs were evident in slices from control (Ctrl = *Bsn*<sup>+/+</sup>) mice (0 out of 16 slices from 5 mice). (C) Summary graph illustrating reduced incidence of SW events in CA1 of *Bsn*<sup>KO</sup> mice. (D) Representative field potential traces illustrating a mild reduction in the SW incidence of *Bsn*<sup>Emx1</sup> mice. (E) Slices obtained from Ctrl mice (0 out of 19 slices from 5 mice) and *Bsn*<sup>Emx1</sup> mice (0 out of 26 slices from 5 mice) exhibited no spontaneous REDs. (F) Summary graph illustrating reduced incidence of SW events in the hippocampal CA1 of *Bsn*<sup>Emx1</sup> mice. (G) Representative field potential traces illustrating reduced SW incidence in the hippocampal CA3 of *Bsn*<sup>Dlx5/6</sup> mice. Note the co-presence of spontaneous REDs in slices from *Bsn*<sup>Dlx5/6</sup> mice. (H) About 20% of entorhinal-hippocampal slices of *Bsn*<sup>Dlx5/6</sup> mice (7 out of 34; slices; 4 out of 10 mice) exhibited REDs in addition to SW. No REDs were observed in Ctrl mice (0 out of 33 slices from 8 mice). (I) Summary graph illustrating reduced incidence of SW events in the hippocampal CA3 of *Bsn*<sup>Dlx5/6</sup> mice. Data in C, F and I are presented as mean ± SEM. Data in B, E and H are presented as percent of number of slices included in the study. B, E, H: Fisher's exact test; C, F: Student's two-tailed test; I: CA3: Mann-Whitney *U* test; CA1: Student's two-tailed test. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001.

significantly reduced in CA1 ( $t_{57} = 3.404$ ,  $P = 0.001$ ) of *Bsn*<sup>KO</sup> as compared to control mice (Fig. 3A, C). SW area in CA1 (Mann-Whitney  $U = 247$ ,  $P = 0.019$ ) and CA3 (Mann-Whitney  $U = 109$ ,  $P = 0.007$ ) and ripple amplitude in CA3 (Mann-Whitney  $U = 95$ ,  $P = 0.002$ ) were significantly augmented in the null mutants as compared to controls (Supplementary Fig. S3).

In slices from cKO mice lacking Bassoon in excitatory forebrain neurons, no REDs were observed, while the SW incidence was significantly reduced in CA1 ( $t_{45} = 2.234$ ,  $P = 0.030$ ), but not in CA3 ( $t_{43} =$

$-0.337$ ,  $P = 0.738$ ) (Fig. 3D-F). The SW area (Mann-Whitney  $U = 136$ ,  $P = 0.011$ ) and ripple amplitudes (Mann-Whitney  $U = 153$ ,  $P = 0.032$ ) were augmented and a slight increase in ripple frequency ( $t_{43} = 2.377$ ,  $P = 0.022$ ) was detectable in hippocampal CA3 of *Bsn*<sup>Emx1</sup> mice (Supplementary Fig. S4).

In contrast, about one fifth of slices (20.5%; 7 out of 34 slices; 4 out of 10 mice) from cKO mice lacking Bassoon in GABAergic interneurons displayed REDs (Fig. 3G, H). A clearly reduced SW incidence was detectable in the CA3 (Mann-Whitney  $U = 212.5$ ,  $P < 0.001$ ), but not




the CA1 region ( $t_{(59)} = -0.0494$ ,  $P = 0.961$ ) of the *Bsn<sup>Dlx5/6</sup>* mice as compared to controls (Fig. 3G, I). In addition, increased ripple frequencies were detected in these mice (CA3:  $t_{(60)} = -2.904$ ,  $P = 0.005$ ; CA1:  $t_{(59)} = -2.086$ ,  $P = 0.041$ ) (Supplementary Fig. S5).

These data disclose an increased propensity for the generation of spontaneous REDs in entorhinal-hippocampal slices of *Bsn<sup>KO</sup>* and *Bsn<sup>Dlx5/6</sup>* mice consistent with the observed severity of epileptic phenotype developed by these mice as compared to the *Bsn<sup>Emx1</sup>* line, and suggest that disturbed interneuron functions strongly contribute to the epileptic phenotype.

To discover potential changes at individual inhibitory synapses we used a primary culture system of hippocampal neurons from *Bsn<sup>Dlx5/6</sup>* cKO mice. To this end, we first detected the presence or absence of Bassoon at synapses within these cultures. About one third of inhibitory synapses identified via immunodetection of the vesicular transporter for GABA (VGAT) lack Bassoon immunoreactivity, whereas basically all

excitatory synapses identified by expression of vesicular transporter of glutamate (VGLUT1) are positive for Bassoon antibody staining (Supplementary Fig. S6A, B, C). To assess for the functionality of inhibitory synapses, we performed uptake assays for fluorescence-labeled antibodies detecting the luminal part of the synaptic vesicle protein synaptotagmin-1 (Kraszewski et al., 1995). When added to the primary culture, this antibody is taken up into the presynapse during *exo*- and subsequent endocytosis steps of the synaptic vesicle cycle and the uptake is a measure for neurotransmitter release from these synapses under basal network activity. Under these conditions we find a net reduction synaptic vesicle cycling at inhibitory synapses in *Bsn<sup>Dlx5/6</sup>* cKO vs. WT cultures (Supplementary Fig. S6D, E), suggesting a reduced synaptic strength of inhibitory synapses lacking Bassoon.



**Fig. 4.** Differences in the signature of components of the hyaluronan-based neural ECM in subcellular forebrain fractions from the different epilepsy models. (A) homogenate fractions; (B) soluble fractions; (C) synaptosomal fractions. Subpanels (a) show heatmaps indicating the levels of all ECM components investigated in the homogenates (A.c), soluble fractions (B.c), and synaptosomes (C.c) of all animal groups, relative to their respective controls. Significant changes are marked with asterisks. Color bar indicates protein level changes. Subpanels (b) show comparisons of the levels of Hapln4 in the homogenate fraction (A.b), of full-length Brevican in the soluble fraction (B.b) and of 250 kDa Aggrecan in the synaptosomal fraction (C.b) in mutants to their respective controls. Subpanels (c) show examples of original immunoblots for Hapln4 in the homogenate of *Bsn<sup>gt</sup>* and *KA<sup>1wk</sup>* mice (A.c), for Brevican in the soluble fractions of *Bsn<sup>KO</sup>* and *KA<sup>1wk</sup>* mice (B.c), and for synaptosomal 250 kDa Aggrecan fragment in *Bsn<sup>Dlx5/6</sup>* and *KA<sup>1wk</sup>* mice (C.c). Molecular mass of bands is indicated (in kDa). (Statistics: Student's or Welch's *t*-test, or Mann-Whitney rank sum test depending on equal variance and normality of compared samples; \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ). Note that Tenascin-R (TNR) was only quantified in the homogenate fraction as immunoblot signals in the soluble and synaptosomal subfractions were too weak to allow reliable assessment.



### 3.4. Epilepsy-related changes in the ECM in subcellular protein fractions

The ECM surrounding neurons is modified following seizures (Dityatev, 2010). Therefore, we next aimed to compare epilepsy-related changes in the hyaluronan-based ECM to search for correlations between epilepsy phenotype characteristics and altered ECM patterns in the different mouse groups. How do seizure severity and frequency affect ECM composition? The HA-based matrix is strongly enriched in PNNs, but is also widely distributed in the brain parenchyma filling the entire extracellular space and in particular wrapping synaptic junctions (Dityatev et al., 2010). To study the alterations in the ECM in the different epilepsy models, we collected the forebrains of animals after the EEG recordings (for the experimental schedule see Supplementary Fig. S2) and isolated subcellular fractions. The homogenate fraction (Hom) was obtained after removal of debris, the soluble fraction (Sol) contains intracellular and extracellular proteins not associated with macromolecular complexes, membranes, and organelles, and the synaptosomal fraction (Syn) comprises synaptic and perisynaptic material. Indeed, we found the ECM composition to be differentially regulated in our epilepsy models with some regulations being specific to the soluble or synaptosomal subcellular fractions, indicating particular changes in solubility or synapse association (Fig. 4). In the brain samples of weakly epileptic *Bsn<sup>Emx1</sup>* mice, we did not observe any difference to controls. In the samples of the KA-treated animals, only one statistically significant change was found for Brevican levels, which were reduced in KA<sup>4wk</sup> homogenates (Fig. 4 Aa). In the epileptic *Bsn* mouse models, a distinct pattern of ECM regulation evolved, with clear upregulation of Aggrecan and Hapln4 in the homogenates of *Bsn<sup>Dlx5/6</sup>* and *Bsn<sup>gf</sup>* mice, respectively (Fig. 4 Aa-c). Together with 130 kDa Neurocan fragment and with the link protein Hapln1, Aggrecan and its major cleavage product were also upregulated in the soluble fractions (Fig. 4 Ba). Finally, in the synaptosomal fractions strongest effects were found for Hapln4, 250 kDa Aggrecan and 130 kDa Neurocan, all being enriched in *Bsn*-deficient epileptic mice (Fig. 4 Ca). It is noticeable that full-length Brevican clearly stands out because this is the only significantly downregulated molecule among all investigated candidates (Fig. 4 Aa, Ba-c, Ca).

In the epileptic *Bsn<sup>gf</sup>* line we detected several differences but only the upregulation of Hapln4 survived statistical testing (Fig. 4 Aa), while differences in the other investigated molecules, e.g. in Tenascin-C, did not reach significance, potentially due to higher within-group variability in this strain.

Increased neuronal activity and plasticity reportedly can induce cleavage of ECM components (Dityatev et al., 2007; Mitlöchner et al., 2020; Valenzuela et al., 2014). Interestingly, the ratio between 80 kDa cleaved and total Brevican was significantly increased in the homogenate fractions of the highly epileptic *Bsn<sup>gf</sup>* mutants and also in the soluble and synaptosomal fractions of *Bsn<sup>KO</sup>* mice, but not in any of the kainate animal samples. This strong increase in proteolysis seems to be Brevican-specific, as neither for Aggrecan nor for Neurocan a similar difference in cleavage ratios was observed (Supplementary Fig. S7).

As the animals varied in age (between 4 and 8 months) and genetic background (C57BL6N for *Bsn* lines and C57BL6J for KA groups), we considered age and background as potential covariates, however, three-way ANCOVA did not reveal any effect of age or background on any of the ECM measures (Supplementary Table S1). In contrast, group effects are highly significant for most ECM measures (e.g., for Aggrecan, Brevican, and the ratio of cleaved to total Brevican,  $P < 0.0001$ ; Supplementary Table S1).

### 3.5. Multivariate analyses of ECM changes in epilepsy models


To detect characteristic signatures of ECM rearrangement, we performed a correlation analysis which revealed a complex pattern of interdependencies between expression and cleavage of ECM proteins in various subcellular fractions and significant correlations between seizure and ECM parameters (Supplementary Fig. S8). To

simultaneously consider and represent ECM remodeling in all studied epilepsy models, a linear multivariate discriminant analysis was performed. The differences between epilepsy models were optimally projected in the space of two factors constructed as linear combinations of multiple ECM measures (Fig. 5A). The first factor explaining 40.59% of the total variance was most negatively correlated with the expression of total and cleaved Brevican in the soluble fractions and the cleaved Neurocan in the homogenate, and positively correlated with the ratios between the cleaved and total Brevican in the soluble fraction and the homogenate and Hapln4 in the homogenate. The second factor explaining 24.09% of the total variance was most negatively correlated with the expression of soluble Hapln4 and cleaved Brevican in the homogenate and the soluble fraction. The ratio between the cleaved and total Brevican in synaptosomes and the levels of cleaved Aggrecan and Neurocan in the homogenate were the most positively correlated ECM measures with the second factor. Thus, it appears that the first and second factors predominantly represent changes in Brevican but also in Neurocan, Aggrecan and Hapln4. The discriminant analysis demonstrates that (i) the most dramatic alterations in ECM measures related to the first factor were observed in *Bsn<sup>KO</sup>* mice; (ii) ECM remodeling in *Bsn<sup>gf</sup>* mice was in the same direction as in *Bsn<sup>KO</sup>* mice but milder (this is in line with the analysis of individual ECM measures, which revealed the most distinct ECM remodeling in *Bsn<sup>KO</sup>* and *Bsn<sup>gf</sup>* mice); (iii) the second factor revealed differences between other studied models of epilepsy, KA<sup>4wk</sup> and *Bsn<sup>Emx1</sup>* were most distinct in the second factor from control mice as compared to *Bsn<sup>ΔEx4/5</sup>*, *Bsn<sup>Dlx5/6</sup>*, and KA<sup>1wk</sup> mice.

Multivariate linear regression analysis was used to determine if linear combinations of ECM measures would allow to predict the frequency and duration of seizures, and the fraction of LVF seizures (Fig. 5B). Among significant predictors of seizure frequency were four ECM measures (Fig. 5B) overlapping with the first factor revealed by the discriminant analysis and predominantly reflecting Brevican proteolytic cleavage in the soluble fraction. Six significant predictors of the seizure duration for mice which experienced seizures reflected the levels of Brevican, Aggrecan, Hapln1 and Hapln4 in different brain fractions. Among six significant predictors of the LVF seizures (involving failures in GABAergic transmission), two were related to Aggrecan and others to Neurocan, Brevican and Hapln4. The ECM parameters explained 69.6%, 83.8%, and 91.3% of the total variance in the seizure frequency, duration of seizures, and the fraction of LVF seizures, respectively. Adding age and genetic background in the regression analysis only marginally improved the prediction of seizure frequency by 7.3%, the fraction of LVF by 4.1% and did not improve the prediction of seizure duration. This is in line with a significant negative correlation between age and seizure frequency ( $R^2 = 0.174$ ,  $p = 0.005$ ), which is solely driven by the KA<sup>4wk</sup> group, and a lack of correlation between age and seizure duration ( $R^2 = 0.011$ ,  $p = 0.618$ ) or LVF ( $R^2 = 0.029$ ,  $p = 0.483$ ) (Fig. S9). It is obvious from Fig. 5B that the revealed relationships between ECM measures and seizure parameters are valid within different mouse lines (e.g. blue and green points corresponding to *Bsn<sup>KO</sup>* and *Bsn<sup>gf</sup>* mice, respectively), particularly for the seizure duration and the fraction of LVF seizures. These data highlight a clear link between ECM remodeling to ictogenesis and/or epileptogenesis.

### 3.6. Spatial distribution of epilepsy-associated ECM changes


To evaluate where in the brain epilepsy-related ECM remodeling is most pronounced, we performed immunohistochemistry in *Bsn<sup>KO</sup>* mice and compared the patterns of WFA labeling and of Brevican immunolocalization with wildtype control patterns (Supplementary Fig. S10). The plant lectin WFA is a widely used indicator for a PNN-typical glycosaminoglycan subtype, which is preferentially linked to Aggrecan (Härtig et al., 2022). We found a wide-spread and evident upregulation of WFA-binding chondroitin sulfates paralleled by an overall loss of Brevican, with both effects being most pronounced in the hippocampus. Therefore, we focused on this brain area for a detailed comparison of our



**Fig. 5.** Multivariate analyses of ECM remodeling in mouse models of epilepsy. (A) Linear multivariate discriminant analysis was used to optimally represent differences in the ECM composition between all studied mouse models in the space of two factors constructed as linear combination of studied ECM measures. Three ECM measures most negatively or positively correlating with each of the factors are listed next to axes. The ellipsoids outlining data from the same model were added manually to facilitate perception of the relationships between models. (B) Linear multivariate regression analysis was used to determine the ECM measures optimally predicting the frequency and duration of seizures, and proportion of low-voltage fast (%LVF) onsets seizures. Scattergrams depicting the relationships between the observed and predicted seizure parameters are shown with the same color coding as in panel (A). The dashed lines are the lines of identity. The adjusted  $R^2$  values provide the fraction of total variance explained by multivariate linear regression model. The best predictors are listed below scatterplots, with their significance: \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .

different Bassoon-deficient lines (Fig. 6). We observed Brevican down- and WFA up-regulation strongest in the full knockout and also detectable in the GABAergic neuron-specific knockout *Bsn<sup>Dlx5/6</sup>*, the lines displaying the strongest epileptic phenotypes. Increased WFA signal was concentrated in the granular and molecular layers of the dentate gyrus,

but also associated with individual neurons in the CA1 region. Similar upregulation of WFA in the dentate gyrus was found in *KA<sup>4wk</sup>* mice (Supplementary Fig. S11).



**Fig. 6.** Lectin- and immuno-histochemical distribution of *Wisteria floribunda* agglutinin (WFA; green) and Brevican (Bcan; purple) in the hippocampus of Bassoon-mutant lines *Bsn*<sup>KO</sup>, *Bsn*<sup>Emx1</sup>, *Bsn*<sup>Dlx5/6</sup>. The floxed mouse *Bsn*<sup>lx/lx</sup> served as control. Scale bar: 500  $\mu$ m.

### 3.7. The ECM receptor CD44 is upregulated in epileptic mice

In search for a cellular mechanism of disturbed cell-ECM communication we performed a proteomic screen with membrane fractions from brains from *Bsn*-deficient lines *Bsn*<sup>KO</sup>, *Bsn*<sup>Emx1</sup> and *Bsn*<sup>Dlx5/6</sup> and identified the hyaluronan receptor CD44 as a candidate molecule with increased expression in Bassoon full (*Bsn*<sup>KO</sup>) and inhibitory neuron-specific (*Bsn*<sup>Dlx5/6</sup>) knockout mice. With immunoblotting we confirmed a two- to three-fold upregulation of CD44 in the complete (two-way ANOVA, post-hoc Šidák;  $M = 2.72$  A.U.,  $SD = 0.73$ ,  $P = 0.0008$ ) as well as in the inhibitory neuron-specific ( $M = 2$  A.U.,  $SD = 0.31$ ,  $P = 0.09$ ), but not in the weakly epileptic excitatory neuron-specific knockout ( $M = 1.1$  A.U.,  $SD = 0.3$ ,  $P = 0.99$ ) (Fig. 7). Interestingly, this increase in CD44 immunoreactivity occurred also in the kainate model one week after injection ( $M = 3.08$  A.U.,  $SD = 1.33$ ,  $P < 0.0001$ ), and it was also detected in the synaptosomal fractions (*Bsn*<sup>KO</sup>  $M = 2.56$  A.U.,  $SD = 0.71$ ,  $P = 0.011$ ; *Bsn*<sup>Dlx5/6</sup>  $M = 2.33$  A.U.,  $SD = 0.7$ ,  $P = 0.041$ ) (Fig. 7A-B), suggesting increased perisynaptic ECM binding in epileptic brains. Immunohistochemistry revealed major increase in CD44 immunolabel in the molecular layer of the dentate gyrus as well as in the CA1 stratum lacunosum moleculare (Fig. 7C). Double labeling with anti-GFAP antibodies reveals no co-localization, indicating that the increased CD44 levels are unlikely to be produced by astroglial cells (Fig. 7C).

## 4. Discussion


Here we provide evidence that *Bsn* deletion in all synapses or in a subset of GABAergic synapses causes severe epilepsy with more and stronger seizures than hippocampal kainate injection, while excitatory forebrain neuron-specific *Bsn* deficiency caused only mild seizure activity. Mouse model-specific patterns of neural ECM remodeling reliably predicted seizure properties across models, suggesting a mechanistical link between ECM state and epileptic phenotype.

### 4.1. Bassoon mutants as suitable models for human epilepsy

We demonstrated that all three constitutive *Bsn* mouse mutants develop severe epilepsy in homozygosity with high seizure-induced lethality (~50%) between 3 and 30 weeks of postnatal life. Reduced ratios of homozygous animals point to high lethality before genotyping, although reduced fertilization rates by mutated germ cells cannot be excluded. Indeed, viable homozygous mutant animals do not breed. Also, all *Bsn*<sup>Dlx5/6</sup> inhibitory neuron-specific cKO mice develop seizures and display increased lethality between postnatal weeks 3 and 5, while *Bsn*<sup>Emx1</sup> excitatory neuron-specific cKO mice display similar survival rates to control mice and clearly lower seizure incidence.

The majority of patients carrying recently identified *BSN* mutations affecting primarily the C-terminal region of Bassoon (Ye et al., 2022)





(caption on next page)



**Fig. 7.** Upregulation of CD44 in epileptic Bassoon mouse lines as well as in the KA model. **(A)** Immunoblot examples showing CD44 immunoreactivity in the homogenate and synaptosomal fractions of *Bsn*<sup>KO</sup> and *Bsn*<sup>Dbx5/6</sup> as well as KA<sup>1wk</sup> mouse forebrains. **(B)** Quantification of CD44 immunoreactivity in the constitutive (*Bsn*<sup>KO</sup>, blue), the excitatory neuron-specific (*Bsn*<sup>Emx1</sup>, purple) and the inhibitory neuron-specific (*Bsn*<sup>Dbx5/6</sup>, ochre) Bassoon-deficient mouse lines as well as in kainate-treated mice (KA<sup>1wk</sup>, violet; KA<sup>4wk</sup>, brown) as compared to their corresponding controls (black dots). **(C)** Immunohistochemical localization of CD44 immunoreactivity (yellow) in control (WT) and Bassoon-mutant (*Bsn*<sup>KO</sup>) mouse hippocampus. Astrocytes are labeled with anti-GFAP (purple); DAPI staining is shown in cyan. Scale bar: 500  $\mu$ m. Two-way ANOVA with Sidak's multiple comparisons of KO/KA and WT/Ctrl, \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001.

displayed infancy or childhood onset epilepsies frequently with a history of febrile convulsions. Most of these human mutations seem to have a benign outcome letting the authors speculate that, like in mice, more severe mutations in humans may be fatal (Ye et al., 2022).

An intriguing finding here is that a major contribution to the seizure-inducing pathology originates from Bassoon deletion in GABAergic interneurons. In vivo, seizures are paralleled by spontaneous recurrent epileptiform discharges in hippocampal slices of *Bsn*<sup>Dbx5/6</sup>cKO mice, which occur at similar rates in constitutive knockouts but are absent from mice lacking Bassoon at excitatory forebrain synapses only (Fig. 3). Sharp-wave ripples, complex oscillatory patterns originating from the hippocampus, are considered as hallmarks of episodic memory encoding and behavioral planning (Buzsaki, 2015). As observed in epileptic *Bsn*<sup>Dbx5/6</sup> or *Bsn*<sup>KO</sup> mice, reduced SW generation and/or emergence of fast ripple oscillations have been consistently demonstrated in other genetic and pharmacologically-induced (e.g., kainic acid) epilepsy models both in vivo and in vitro (Bragin et al., 2004; Cheah et al., 2019; Engel Jr. et al., 2009; Foffani et al., 2007; Jefferys et al., 2012; Lippmann et al., 2022). Furthermore, reduced GABAergic inhibition can lead to pathological conversion of SW-Rs into REDs (Liotta et al., 2011). Indeed, ablation of Bassoon in inhibitory interneurons causes reduced transmission at inhibitory synapses in primary hippocampal cultures, likely causing disinhibition. Earlier studies on *Bsn*<sup>ΔEx4/5</sup> mice lacking functional Bassoon at all chemical brain synapses revealed an abnormal NMDA receptor-dependent short-term potentiation in striatal fast-spiking GABAergic interneurons that was absent in wild-type animals (Ghiglieri et al., 2009) and seems to be triggered via the BDNF/TrkB system (Ghiglieri et al., 2010). Reportedly, BDNF levels are increased in epilepsy (Binder et al., 2001) and BDNF has crucial effects on interneuron development (Bolton et al., 2000; Ghiglieri et al., 2011; Huang et al., 1999; Marty et al., 1997; Willis et al., 2022). Interestingly, BDNF binds to and forms complexes with glycosaminoglycan components in the neural ECM, like chondroitin sulfates (Kanato et al., 2009), and digestion of chondroitin sulphates in the ECM reopens critical period-like plasticity by promoting BDNF signaling in PV+ neurons through inhibition of TrkB dephosphorylation by the PTP $\alpha$ -CSPG complex (Lesnikova et al., 2021).

#### 4.2. Epilepsy-associated ECM remodeling

Differences in the expression of ECM components at various stages of epilepsy have been reported (Soleman et al., 2013). For instance, upregulation of chondroitin sulfates and hyaluronic acid was shown in post-mortem hippocampi of mesial TLE patients (Perosa et al., 2002). However, most studies focused on PNNs as most striking neural ECM formations (Chaunsali et al., 2021). Our data show that under epileptic conditions not only PNNs as largely insoluble condensed ECM structures, but also the composition of soluble and perisynaptic ECM are widely affected.

Coming to individual ECM molecules, we discovered correlations between epileptic seizures and the expression Hapln4/Bral2, a link protein which colocalizes with Brevican in PNN (Bekku et al., 2003) and is involved in the regulation of GABAergic synapses (Edamatsu et al., 2018). Surprisingly, Hapln4 regulation is oppositely affected in our genetic and chemical epilepsy models with higher amounts in homogenates and synaptosomal fractions of *Bsn*-deficient mice while KA-injected mice have a tendency for reduced Hapln4 levels, arguing for a differential regulation of this key ECM and PNN component.

The proteoglycan Neurocan was already discussed in other epilepsy models: Okamoto et al. (2003) demonstrated a temporary rise of Neurocan after systemic KA application causing severe convulsions in rats. Another study showed a transient increase in mice after intra-hippocampal injection of domoate, a kainate-related neurotoxin (Heck et al., 2004). This is partly confirmed by our finding of a significant rise in the 130 kDa Neurocan fragment, an astrocyte-secreted inhibitor of N-cadherin- and  $\beta$ 1-integrin-mediated adhesion and neurite outgrowth (Li et al., 2000).

For Tenascin-R, an increase of immunoreactivity was detected in the hippocampal CA3 neuropil after pilocarpine-induced status epilepticus in mice (Brenneke et al., 2004), whereas here we did not find significant differences between experimental groups. Another study revealed in the pilocarpine model reduced expression of Aggrecan and Hapln1 (McRae et al., 2012), two ECM components, which were upregulated in some *Bsn* mutants pointing to mechanistic differences between the pilocarpine and our models.

In the present study, strongest downregulation was observed for Brevican, one of the most prominent components of the adult perisynaptic and diffuse ECM that is also present in PNNs. This finding is in line with reduced Brevican levels in surgical resections of TLE patients (Favuzzi et al., 2017). Another study reported upregulated Brevican levels in human post-mortem frontal cortex samples from epilepsy patients (Pires et al., 2021), but post-mortem intervals in the control group were more than twice as long as in the epilepsy group, which may cause artificial differences. Finally, our finding of increased Brevican cleavage in Bassoon-deficient epileptic mice corresponds to an earlier report about augmented Brevican proteolysis by ADAMTS in KA-treated rats (Yuan et al., 2002).

In sum, soluble as well as condensed forms of neural ECM become depleted for Brevican but enriched for Aggrecan, WFA-binding glycosaminoglycans and the Neurocan N-terminal fragment. Various mechanisms may underlie these selective ECM reorganization patterns, including seizure-dependent changes in ECM synthesis, post-translational exocytosis and incorporation into PNN. Also, proteolytic processing (see below), ECM endocytosis and clearance or seizure-enhanced autophagy (Otabe et al., 2014), a cellular process which is at presynapses at least in part under the control of Bassoon (Hoffmann-Conaway et al., 2020; Okerlund et al., 2017) might play a role.

A potential mechanistic hub could be the strongly over-expressed HA receptor CD44, which was already shown to be upregulated under different epileptic conditions, e.g. in KA-treated hippocampal slice cultures (Bausch, 2006) and in pilocarpine-injected mice (Borges et al., 2004). CD44 is expressed in synapses and considered as a modulator of synaptic plasticity (Roszkowska et al., 2016) and reorganizer of neuronal and synaptic circuitry after axon terminal degeneration (Borges et al., 2004).

#### 4.3. Functional implications of seizure-associated ECM remodeling

The strong correlation between seizure parameters and expression of ECM molecules can be either due to seizure-dependent proteolytic ECM remodeling or to modulation of neuronal physiology and synaptic connectivity downstream of ECM remodeling. Evidence that MMP9 knockout or pharmacological inhibition of MMP2/9 strongly suppressed ictal activity and epileptogenesis in different models of epilepsy (Broekaart et al., 2021; Wilczynski et al., 2008) and experiments demonstrating degradation of PNNs by MMP9 under various conditions (Dwir

et al., 2020; Stamenkovic et al., 2017; Wen et al., 2018) suggest that MMP9-dependent remodeling of PNNs might determine key aspects of epileptogenesis. Pooling data from several mouse models with genetic and acquired forms of epilepsy, we report here that parameters describing Brevican cleavage in soluble and synaptosomal fractions are the best predictors of the frequency and duration of seizures. This is in line with studies showing that digestion of PNNs with ChABC or conditional depletion of Brevican expression in PV+ cells impairs excitatory input to these GABAergic interneurons (Favuzzi et al., 2017; Hayani et al., 2018), which could result in insufficient recruitment of PV+ interneurons during bursts of network activity and, eventually, in ictal events. Interestingly, expression of neuronal activity-regulated pentraxin (Narp) is strongly upregulated by seizures and might promote AMPA receptor accumulation in excitatory synapses on PV+ cells (Chang et al., 2010). However, Narp stabilization requires the integrity of perisynaptic ECM of PNNs. When the latter is degraded due to elevated endogenous proteinase activity or enzymatic treatment with hyaluronidase (Vedunova et al., 2013), this powerful endogenous anti-epileptic mechanism can be compromised, resulting in the generation of epileptiform activity.

Moreover, a conditional knockout of Aggrecan in PV+ cells ablated PNNs and caused a shift in the population of parvalbumin-expressing inhibitory interneurons toward a high plasticity state (Rowlands et al., 2018). Enzymatic attenuation of Aggrecan-enriched PNNs or depletion of Brevican also lead to increased excitability of PV+ interneurons (Dityatev et al., 2007; Favuzzi et al., 2017; Hayani et al., 2018). Tenascin-R-deficient mice exhibit an increased excitatory input to excitatory neurons and decreased perisomatic inhibition in the CA1 region of the hippocampus (Saghatelian et al., 2001). These data suggest a complex dependence of synaptic innervation, excitability and plasticity of PV+ cells on the ECM of PNNs. Remodeling of PNNs appeared to be of functional relevance to LVF onset seizures because i) a highly significant prediction of the proportion of such seizures by a linear combination of parameters describing proteolysis of PNN-associated ECM proteoglycans, as found in the present study, and ii) previous recordings in rodent models and in human TLE patients, which revealed that seizure-like events with LVF onset are initiated by synchronous inhibitory discharges (Avoli et al., 2016; Elahian et al., 2018). In this context, it is surprising that *Bsn*<sup>Dlx5/6</sup> cKO mice display mostly this onset type although presynaptic GABAergic function seems to be reduced in primary cultures derived from these animals. More detailed studies - including analyses of postsynaptic inhibitory postsynaptic currents and excitability of PV-expressing interneurons - in this particular mouse model will be necessary to resolve this ambiguity and gain further insight into onset mechanisms of seizures.

Analysis of ECM expression in synaptosomal fractions (highly enriched in excitatory synapses) revealed that cleavage of Brevican and Neurocan and the levels of Hapln1 and Hapln4 are among predictors of seizure type and duration, suggesting that also remodeling of perisynaptic ECM at excitatory synapses on principal cells may be relevant to synaptic remodeling underlying epilepto- and/or ictogenesis. A previous modeling study supports the view that activity-dependent proteolysis of ECM may lead to a switch in the steady state of ECM expression and neuronal activity (Lazarevich et al., 2020). Moreover, proteolysis of ECM molecules has been associated with the key hallmarks of TLE such as granule cell dispersion, mossy fiber sprouting and astrogliosis (Dityatev and Fellin, 2009; Dityatev, 2010). Further studies with brain region- and cell type-specific expression of proteolysis-resistant forms of ECM molecules are warranted to dissect multiple mechanisms by which ECM remodeling leads to formation of hyperexcitable networks.

#### Significance and Limitations of the Study, Outlook

- Although in our study we did not exactly model human epilepsy-related mutations but rather used full gene deletions, we provide clear evidence for *Bsn* as a genuine epilepsy gene, which most likely causes early-onset epilepsies.

- Furthermore, from our findings in *Bsn*<sup>Dlx5/6</sup> mice we can conclude that *Bsn* deletion particularly in inhibitory synapses is crucial for the epileptic phenotypes, but the exact mechanisms of epileptogenesis still need to be unraveled.
- Although all mice investigated were young adult to adult, due to age differences between *Bsn*<sup>Dlx5/6</sup> and *Bsn*<sup>Emx1</sup> during testing an age effect on seizure parameters cannot completely be ruled out.
- Upon more comprehensive characterization the *Bsn*<sup>Dlx5/6</sup> mouse could be an interesting model to clarify how LVF onset seizures evolve, because it frequently expresses this onset type and has a deletion of Bassoon only in a subset of inhibitory neurons.
- We provide insight into the neural ECM remodeling capacity in different epilepsy models, but so far we cannot discriminate if the matrix reorganization is causative for seizures or rather a consequence of epileptic discharges, because the early-onset models do not allow to test ECM composition before and after epileptogenesis. Furthermore, it is not yet known how stable these rearrangements are over lifetime, and if inhibition of ECM remodeling could prevent epileptogenesis in *Bsn*-deficient mice.
- Pharmacological studies using antiseizure medication in the *Bsn* mutant mouse lines could help to investigate if ECM remodeling occurs also in treated animals, and if it is reversible before and after treatment.
- The fact that the proteoglycan Brevican stands out because it was the only neural ECM component which was consistently downregulated, while all other investigated molecules were upregulated, points to a specific role of this proteoglycan in epileptic brains, which needs to be investigated further.

#### CRediT authorship contribution statement

**Armand Blondiaux:** Data curation, Formal analysis, Investigation, Writing – original draft, Writing – review & editing. **Shaobo Jia:** Data curation, Formal analysis, Investigation, Writing – review & editing. **Anil Annamneedi:** Funding acquisition, Investigation, Writing – review & editing. **Gürsel Çalışkan:** Formal analysis, Investigation, Writing – review & editing. **Jana Nebel:** Formal analysis, Investigation, Writing – review & editing. **Carolina Montenegro-Venegas:** Formal analysis, Investigation, Writing – review & editing. **Robert C. Wykes:** Formal analysis, Methodology, Resources, Writing – review & editing. **Anna Fejtova:** Methodology, Resources, Writing – review & editing. **Matthew C. Walker:** Formal analysis, Methodology, Resources, Writing – review & editing. **Oliver Stork:** Formal analysis, Project administration, Supervision, Writing – review & editing. **Eckart D. Gundelfinger:** Conceptualization, Funding acquisition, Project administration, Supervision, Writing – original draft, Writing – review & editing. **Alexander Dityatev:** Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing. **Constanze I. Seidenbecher:** Conceptualization, Funding acquisition, Project administration, Supervision, Writing – original draft, Writing – review & editing.

#### Data availability

Data will be made available on request.

#### Acknowledgements

The authors gratefully acknowledge expert technical support by Kathrin Hartung, Michelle Wirsum, Kathrin Pohlmann, Isabel Herbert and animal caretakers at LIN. We would like to thank Karl-Heinz Smalla for valuable advice on the protein biochemistry and Izel Avci for technical assistance in quantitative analysis of primary neuronal cultures. A. B. and S.J. were fellows of the Marie Curie ITN ECMED (Grant agreement ID: 642881). A.B. and A.A. were supported by a LINseeds grant. J. N. is a member of the SynAGE graduate program. Research in the

authors' labs is supported by the Deutsche Forschungsgemeinschaft (362321501/RTG 2413 SynAGE to A.D., E.D.G. and C.I.S. and 425899996/CRC1436 to A.D. and C.I.S.). The work was also supported by grants from Center for Behavioral Brain Sciences (CBBS, promoted by Europäischer Fonds für regionale Entwicklung - EFRE (ZS/2016/04/78113) and CBBS ScienceCampus funded by the Leibniz Association (SAS-2015-LIN-LWC) to G.C., A.A. and C.M.-V.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.nbd.2023.106324>.

## References

- Altrock, W.D., Tom Dieck, S., Sokolov, M., Meyer, A.C., Sigler, A., Brakebusch, C., Fassler, R., Richter, K., Boeckers, T.M., Potschka, H., Brandt, C., Loscher, W., Grimberg, D., Dresbach, T., Hempelmann, A., Hassan, H., Balschun, D., Frey, J.U., Brandstatter, J.H., Garner, C.C., Rosenmund, C., Gundelfinger, E.D., 2003. Functional inactivation of a fraction of excitatory synapses in mice deficient for the active zone protein bassoon. *Neuron* 37, 787–800. [https://doi.org/10.1016/S0896-6273\(03\)00088-6](https://doi.org/10.1016/S0896-6273(03)00088-6).
- Angenstein, F., Niessen, H.G., Goldschmidt, J., Lison, H., Altrock, W.D., Gundelfinger, E. D., Scheich, H., 2007. Manganese-enhanced MRI reveals structural and functional changes in the cortex of bassoon mutant mice. *Cereb. Cortex* 17, 28–36. <https://doi.org/10.1093/cercor/bhj121>.
- Angenstein, F., Hilfirt, L., Zuschratter, W., Altrock, W.D., Niessen, H.G., Gundelfinger, E. D., 2008. Morphological and metabolic changes in the cortex of mice lacking the functional presynaptic active zone protein bassoon: a combined 1H-NMR spectroscopy and histochemical study. *Cereb. Cortex* 18, 890–897. <https://doi.org/10.1093/cercor/bhm122>.
- Annamneedi, A., Caliskan, G., Muller, S., Montag, D., Budinger, E., Angenstein, F., Fejtova, A., Tischmeyer, W., Gundelfinger, E.D., Stork, O., 2018. Ablation of the presynaptic organizer bassoon in excitatory neurons retards dentate gyrus maturation and enhances learning performance. *Brain Struct. Funct.* 223, 3423–3445. <https://doi.org/10.1007/s00429-018-1692-3>.
- Arranz, A.M., Perkins, K.L., Irie, F., Lewis, D.P., Hrabe, J., Xiao, F., Itano, N., Kimata, K., Hrabetova, S., Yamaguchi, Y., 2014. Hyaluronan deficiency due to Has3 knock-out causes altered neuronal activity and seizures via reduction in brain extracellular space. *J. Neurosci.* 34, 6164–6176. <https://doi.org/10.1523/JNEUROSCI.3458-13.2014>.
- Avoli, M., de Curtis, M., Gnatkovsky, V., Gotman, J., Kohling, R., Levesque, M., Manseau, F., Shiri, Z., Williams, S., 2016. Specific imbalance of excitatory/inhibitory signaling establishes seizure onset pattern in temporal lobe epilepsy. *J. Neurophysiol.* 115, 3229–3237. <https://doi.org/10.1152/jn.01128.2015>.
- Balestrini, S., Arzimanoglou, A., Blumcke, I., Scheffer, I.E., Wiebe, S., Zelano, J., Walker, M.C., 2021. The aetiologies of epilepsy. *Epilept. Disord.* 23, 1–16. <https://doi.org/10.1684/epd.2021.1255>. <https://onlinelibrary.wiley.com/doi/full/10.1684/epd.2021.1255>.
- Bausch, S.B., 2006. Potential roles for hyaluronan and CD44 in kainic acid-induced mossy fiber sprouting in organotypic hippocampal slice cultures. *Neuroscience* 143, 339–350. <https://doi.org/10.1016/j.neuroscience.2006.07.037>.
- Behrens, C.J., van den Boom, L.P., Heinemann, U., 2007. Effects of the GABA(A) receptor antagonists bicuculline and gabazine on stimulus-induced sharp wave-ripple complexes in adult rat hippocampus in vitro. *Eur. J. Neurosci.* 25, 2170–2181. <https://doi.org/10.1111/j.1460-9568.2007.05462.x>.
- Bekku, Y., Su, W.D., Hirakawa, S., Fassler, R., Ohtsuka, A., Kang, J.S., Sanders, J., Murakami, T., Ninomiya, Y., Oohashi, T., 2003. Molecular cloning of Bral2, a novel brain-specific link protein, and immunohistochemical colocalization with brevicin in perineuronal nets. *Mol. Cell. Neurosci.* 24, 148–159. [https://doi.org/10.1016/S1044-7431\(03\)00133-7](https://doi.org/10.1016/S1044-7431(03)00133-7).
- Binder, D.K., Croll, S.D., Gall, C.M., Scharfman, H.E., 2001. BDNF and epilepsy: too much of a good thing? *Trends Neurosci.* 24, 47–53. [https://doi.org/10.1016/S0166-2236\(00\)01682-9](https://doi.org/10.1016/S0166-2236(00)01682-9).
- Bolton, M.M., Pittman, A.J., Lo, D.C., 2000. Brain-derived neurotrophic factor differentially regulates excitatory and inhibitory synaptic transmission in hippocampal cultures. *J. Neurosci.* 20, 3221–3232. <https://doi.org/10.1523/JNEUROSCI.20-09.03221.2000>.
- Borges, K., McDermott, D.L., Dingleline, R., 2004. Reciprocal changes of CD44 and GAP-43 expression in the dentate gyrus inner molecular layer after status epilepticus in mice. *Exp. Neurol.* 188, 1–10. <https://doi.org/10.1016/j.expneurol.2004.03.019>.
- Bouillere, V., Ridoux, V., Depaulis, A., Marescaux, C., Nehlig, A., Le Gal La Salle, G., 1999. Recurrent seizures and hippocampal sclerosis following intrahippocampal kainate injection in adult mice: electroencephalography, histopathology and synaptic reorganization similar to mesial temporal lobe epilepsy. *Neuroscience* 89, 717–729. [https://doi.org/10.1016/S0306-4522\(98\)00401-1](https://doi.org/10.1016/S0306-4522(98)00401-1).
- Bragin, A., Wilson, C.L., Almajano, J., Mody, I., Engel Jr., J., 2004. High-frequency oscillations after status epilepticus: epileptogenesis and seizure genesis. *Epilepsia* 45, 1017–1023. <https://doi.org/10.1111/j.0013-9580.2004.17004.x>.
- Brenneke, F., Bukalo, O., Dityatev, A., Lie, A.A., 2004. Mice deficient for the extracellular matrix glycoprotein tenascin-r show physiological and structural hallmarks of increased hippocampal excitability, but no increased susceptibility to seizures in the pilocarpine model of epilepsy. *Neuroscience* 124, 841–855. <https://doi.org/10.1016/j.neuroscience.2003.11.037>.
- Broekaart, D.W., Bertran, A., Jia, S., Korotkov, A., Senkov, O., Bongaarts, A., Mills, J.D., Anink, J.J., Seco, J., Baayen, J.C., Idema, S., Chabrol, E., Becker, A.J., Wadman, W. J., Tarrago, T., Gorter, J.A., Aronica, E., Prades, R., Dityatev, A., van Vliet, E.A., 2021. The matrix metalloproteinase inhibitor IPR-179 has antiseizure and antiepileptogenic effects. *J. Clin. Invest.* 131, e138332. <https://doi.org/10.1172/JCI138332>.
- Brohus, M., Arsov, T., Wallace, D.A., Jensen, H.H., Nyegaard, M., Crotti, L., Adamski, M., Zhang, Y., Field, M.A., Athanasopoulos, V., Baro, I., Ribeiro de Oliveira-Mendes, B. B., Redon, R., Charpentier, F., Raju, H., DiSilvestre, D., Wei, J., Wang, R., Rafehi, H., Kaspi, A., Bahlo, M., Dick, I.E., Chen, S.R.W., Cook, M.C., Vinueza, C.G., Overgaard, M.T., Schwartz, P.J., 2021. Infanticide vs. inherited cardiac arrhythmias. *Europace* 23, 441–450. <https://doi.org/10.1093/europace/eaab272>.
- Buzsaki, G., 2015. Hippocampal sharp wave-ripple: a cognitive biomarker for episodic memory and planning. *Hippocampus* 25, 1073–1188. <https://doi.org/10.1002/hipo.22488>.
- Caliskan, G., Schulz, S.B., Gruber, D., Behr, J., Heinemann, U., Gerevich, Z., 2015. Corticosterone and corticotropin-releasing factor acutely facilitate gamma oscillations in the hippocampus in vitro. *Eur. J. Neurosci.* 41, 31–44. <https://doi.org/10.1111/ejn.12750>.
- Caliskan, G., Muller, I., Semtner, M., Winkelmann, A., Raza, A.S., Hollnagel, J.O., Rosler, A., Heinemann, U., Stork, O., Meier, J.C., 2016. Identification of Parvalbumin interneurons as cellular substrate of fear memory persistence. *Cereb. Cortex* 26, 2325–2340. <https://doi.org/10.1093/cercor/bhw001>.
- Carlin, R.K., Grab, D.J., Cohen, R.S., Siekevitz, P., 1980. Isolation and characterization of postsynaptic densities from various brain regions: enrichment of different types of postsynaptic densities. *J. Cell Biol.* 86, 831–845. <https://doi.org/10.1083/jcb.86.3.831>.
- Chang, M.C., Park, J.M., Pelkey, K.A., Grabenstatter, H.L., Xu, D., Linden, D.J., Sutula, T. P., McBain, C.J., Worley, P.F., 2010. Narp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons. *Nat. Neurosci.* 13, 1090–1097. <https://doi.org/10.1038/nn.2621>.
- Chamsali, L., Tewari, B.P., Sontheimer, H., 2021. Perineuronal net dynamics in the pathophysiology of epilepsy. *Epilep. Curr.* 21, 273–281. <https://doi.org/10.1177/15357597211018688>.
- Cheah, C.S., Lundstrom, B.N., Catterall, W.A., Oakley, J.C., 2019. Impairment of sharp-wave ripples in a murine model of Dravet syndrome. *J. Neurosci.* 39, 9251–9260. <https://doi.org/10.1523/JNEUROSCI.0890-19.2019>.
- Cheah, C.S., Beckman, M.A., Catterall, W.A., Oakley, J.C., 2021. Sharp-wave ripple frequency and interictal epileptic discharges increase in tandem during thermal induction of seizures in a mouse model of genetic epilepsy. *Front. Cell. Neurosci.* 15, 751762. <https://doi.org/10.3389/fncel.2021.751762>.
- Conroy, J., McGettigan, P.A., McCreary, D., Shah, N., Collins, K., Parry-Fielder, B., Moran, M., Hanrahan, D., Deonna, T.W., Korff, C.M., Webb, D., Ennis, S., Lynch, S. A., King, M.D., 2014. Towards the identification of a genetic basis for Landau-Kleffner syndrome. *Epilepsia* 55, 858–865. <https://doi.org/10.1111/epi.12645>.
- Dick, O., Tom Dieck, S., Altrock, W.D., Ammermuller, J., Weiler, R., Garner, C.C., Gundelfinger, E.D., Brandstatter, J.H., 2003. The presynaptic active zone protein bassoon is essential for photoreceptor ribbon synapse formation in the retina. *Neuron* 37, 775–786. [https://doi.org/10.1016/S0896-6273\(03\)00086-2](https://doi.org/10.1016/S0896-6273(03)00086-2).
- Dieni, S., Matsumoto, T., Dekkers, M., Rauskolb, S., Ionescu, M.S., Deogracias, R., Gundelfinger, E.D., Kojima, M., Nestel, S., Frotscher, M., Barde, Y.A., 2012. BDNF and its pro-peptide are stored in presynaptic dense core vesicles in brain neurons. *J. Cell Biol.* 196, 775–788. <https://doi.org/10.1083/jcb.201201038>.
- Dityatev, A., 2010. Remodeling of extracellular matrix and epileptogenesis. *Epilepsia* 51 (Suppl. 3), 61–65. <https://doi.org/10.1111/j.1528-1167.2010.02612.x>.
- Dityatev, A., Fellin, T., 2009. Extracellular matrix in plasticity and epileptogenesis. *Neuron Glia Biol.* 4, 235–247. <https://doi.org/10.1017/S1740925X09000118>.
- Dityatev, A., Bruckner, G., Dityateva, G., Grosche, J., Kleene, R., Schachner, M., 2007. Activity-dependent formation and functions of chondroitin sulfate-rich extracellular matrix of perineuronal nets. *Dev. Neurobiol.* 67, 570–588. <https://doi.org/10.1002/dneu.20361>.
- Dityatev, A., Seidenbecher, C.I., Schachner, M., 2010. Compartmentalization from the outside: the extracellular matrix and functional microdomains in the brain. *Trends Neurosci.* 33, 503–512. <https://doi.org/10.1016/j.tins.2010.08.003>.
- do Canto, A.M., Donatti, A., Geraldini, J.C., Godoi, A.B., da Rosa, D.C., Lopes-Cendes, I., 2021. Neuroproteomics in epilepsy: what do we know so far? *Front. Mol. Neurosci.* 13, 604158. <https://doi.org/10.3389/fnmol.2020.604158>.
- Dwir, D., Giangreco, B., Xin, L., Tenenbaum, L., Cabungcal, J.H., Steullet, P., Goupil, A., Cleusix, M., Jenni, R., Chtarto, A., Baumann, P.S., Klausner, P., Conus, P., Tirouvanziam, R., Cuenod, M., Do, K.Q., 2020. MMP9/RAGE pathway overactivation mediates redox dysregulation and neuroinflammation, leading to inhibitory/excitatory imbalance: a reverse translation study in schizophrenia patients. *Mol. Psychiatry* 25, 2889–2904. <https://doi.org/10.1038/s41380-019-0393-5>.
- Dzyubenko, E., Fleischer, M., Manrique-Castano, D., Borbor, M., Kleinschmitt, C., Faissner, A., Hermann, D.M., 2021. Inhibitory control in neuronal networks relies on the extracellular matrix integrity. *Cell. Mol. Life Sci.* 78, 5647–5663. <https://doi.org/10.1007/s00018-021-03861-3>.
- Edamatsu, M., Miyano, R., Fujikawa, A., Fujii, F., Hori, T., Sakaba, T., Oohashi, T., 2018. Hapln4/Bral2 is a selective regulator for formation and transmission of GABAergic synapses between Purkinje and deep cerebellar nuclei neurons. *J. Neurochem.* 147, 748–763. <https://doi.org/10.1111/jnc.14571>.
- Elahian, B., Lado, N.E., Mankin, E., Vangala, S., Misra, A., Moxon, K., Fried, I., Sharan, A., Yeasin, M., Staba, R., Bragin, A., Avoli, M., Sperling, M.R., Engel Jr., J.,



- Weiss, S.A., 2018. Low-voltage fast seizures in humans begin with increased interneuron firing. *Ann. Neurol.* 84, 588–600. <https://doi.org/10.1002/ana.25325>.
- Engel Jr., J., Bragin, A., Staba, R., Mody, I., 2009. High-frequency oscillations: what is normal and what is not? *Epilepsia* 50, 598–604. <https://doi.org/10.1111/j.1528-1167.2008.01917.x>.
- Favuzzi, E., Marques-Smith, A., Deogracias, R., Winterflood, C.M., Sanchez-Aguilera, A., Mantoan, L., Maeso, P., Fernandes, C., Ewers, H., Rico, B., 2017. Activity-dependent gating of Parvalbumin interneuron function by the Perineuronal net protein Brevican. *Neuron* 95, 639–655. <https://doi.org/10.1016/j.neuron.2017.06.028>.
- Foffani, G., Uzcategui, Y.G., Gal, B., Menendez de la Prida, L., 2007. Reduced spike-timing reliability correlates with the emergence of fast ripples in the rat epileptic hippocampus. *Neuron* 55, 930–941. <https://doi.org/10.1016/j.neuron.2007.07.040>.
- Froukh, T.J., 2017. Next generation sequencing and genome-wide genotyping identify the genetic causes of intellectual disability in ten consanguineous families from Jordan. *Tohoku J. Exp. Med.* 243, 297–309. <https://doi.org/10.1620/tjem.243.297>.
- Fukata, Y., Fukata, M., 2017. Epilepsy and synaptic proteins. *Curr. Opin. Neurobiol.* 45, 1–8. <https://doi.org/10.1016/j.conb.2017.02.001>.
- Gatto, C.L., Broadie, K., 2010. Genetic controls balancing excitatory and inhibitory synaptogenesis in neurodevelopmental disorder models. *Frontiers Synaptic Neuroscience* 2, 4. <https://doi.org/10.3389/fnsyn.2010.00004>.
- Ghiglieri, V., Picconi, B., Sgobio, C., Bagetta, V., Barone, I., Paille, V., Di Filippo, M., Polli, F., Gardoni, F., Altmann, W., Gundelfinger, E.D., De Sarro, G., Bernardi, G., Ammassari-Teule, M., Di Luca, M., Calabresi, P., 2009. Epilepsy-induced abnormal striatal plasticity in bassoon mutant mice. *Eur. J. Neurosci.* 29, 1979–1993. <https://doi.org/10.1111/j.1460-9568.2009.06733.x>.
- Ghiglieri, V., Sgobio, C., Patassini, S., Bagetta, V., Fejtova, A., Giampa, C., Marinucci, S., Heyden, A., Gundelfinger, E.D., Fusco, F.R., Calabresi, P., Picconi, B., 2010. TrkB/BDNF-dependent striatal plasticity and behavior in a genetic model of epilepsy: modulation by valproic acid. *Neuropsychopharmacology* 35, 1531–1540. <https://doi.org/10.1038/npp.2010.23>.
- Ghiglieri, V., Sgobio, C., Costa, C., Picconi, B., Calabresi, P., 2011. Striatum-hippocampus balance: from physiological behavior to interneuronal pathology. *Prog. Neurobiol.* 94, 102–114. <https://doi.org/10.1016/j.pneurobio.2011.04.005>.
- Grötcke, I., Hoffmann, K., Loscher, W., 2008. Behavioral alterations in a mouse model of temporal lobe epilepsy induced by intrahippocampal injection of kainate. *Exp. Neurol.* 213, 71–83. <https://doi.org/10.1016/j.expneurol.2008.04.036>.
- Gundelfinger, E.D., Fejtova, A., 2012. Molecular organization and plasticity of the cytomatrix at the active zone. *Curr. Opin. Neurobiol.* 22, 423–430. <https://doi.org/10.1016/j.conb.2011.10.005>.
- Gundelfinger, E.D., Reissner, C., Garner, C.C., 2016. Role of bassoon and piccolo in assembly and molecular organization of the Active Zone. *Front. Synaptic Neurosci.* 7, 19. <https://doi.org/10.3389/fnsyn.2015.00019>.
- Hallermann, S., Fejtova, A., Schmidt, H., Weyhersmuller, A., Silver, R.A., Gundelfinger, E.D., Eilers, J., 2010. Bassoon speeds vesicle reloading at a central excitatory synapse. *Neuron* 68, 710–723. <https://doi.org/10.1016/j.neuron.2010.10.026>.
- Härtig, W., Meinicke, A., Michalski, D., Schob, S., Jager, C., 2022. Update on Perineuronal net staining with Wisteria floribunda agglutinin (WFA). *Front. Integr. Neurosci.* 16, 851988. <https://doi.org/10.3389/fnint.2022.851988>.
- Hayani, H., Song, I., Dityatev, A., 2018. Increased excitability and reduced excitatory synaptic input into fast-spiking CA2 interneurons after enzymatic attenuation of extracellular matrix. *Front. Cell. Neurosci.* 12, 149. <https://doi.org/10.3389/fncel.2018.00149>.
- Heck, N., Garwood, J., Loeffler, J.P., Larmet, Y., Faissner, A., 2004. Differential upregulation of extracellular matrix molecules associated with the appearance of granule cell dispersion and mossy fiber sprouting during epileptogenesis in a murine model of temporal lobe epilepsy. *Neuroscience* 129, 309–324. <https://doi.org/10.1016/j.neuroscience.2004.06.078>.
- Heyden, A., Ionescu, M.C., Romorini, S., Kracht, B., Ghiglieri, V., Calabresi, P., Seidenbecher, C., Angenstein, F., Gundelfinger, E.D., 2011. Hippocampal enlargement in bassoon-mutant mice is associated with enhanced neurogenesis, reduced apoptosis, and abnormal BDNF levels. *Cell Tissue Res.* 346, 11–26. <https://doi.org/10.1007/s00441-011-1233-3>.
- Hoffmann-Conaway, S., Brockmann, M.M., Schneider, K., Annamneedi, A., Rahman, K. A., Bruns, C., Textoris-Taube, K., Trimbuch, T., Smalla, K.H., Rosenmund, C., Gundelfinger, E.D., Garner, C.C., Montenegro-Venegas, C., 2020. Parkin contributes to synaptic vesicle autophagy in bassoon-deficient mice. *Elife* 9, e56590. <https://doi.org/10.7554/eLife.56590>.
- Huang, Z.J., Kirkwood, A., Pizzorusso, T., Porciatti, V., Morales, B., Bear, M.F., Maffei, L., Tonegawa, S., 1999. BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex. *Cell* 98, 739–755. [https://doi.org/10.1016/S0092-8674\(00\)81509-3](https://doi.org/10.1016/S0092-8674(00)81509-3).
- Jefferys, J.G.R., Jiruska, P., de Curtis, M., Avoli, M., 2012. Limbic network synchronization and temporal lobe epilepsy. In: Noebels, J.L., Avoli, M.A. Rogawski, Olsen, R.W., Delgado-Escueta, A.V. (Eds.), *Jasper's Basic Mechanisms of the Epilepsies*. Bethesda (MD). <https://www.ncbi.nlm.nih.gov/books/NBK98158/>.
- Jefferys, J., Steinhauser, C., Bedner, P., 2016. Chemically-induced TLE models: topical application. *J. Neurosci. Methods* 260, 53–61. <https://doi.org/10.1016/j.jneumeth.2015.04.011>.
- John, N., Krugel, H., Frischknecht, R., Smalla, K.H., Schultz, C., Kreutz, M.R., Gundelfinger, E.D., Seidenbecher, C., 2006. Brevican-containing perineuronal nets of extracellular matrix in dissociated hippocampal primary cultures. *Mol. Cell. Neurosci.* 31, 774–784. <https://doi.org/10.1016/j.mcn.2006.01.011>.
- John, A., Ng-Cordell, E., Hanna, N., Brkic, D., Baker, K., 2021. The neurodevelopmental spectrum of synaptic vesicle cycling disorders. *J. Neurochem.* 157, 208–228. <https://doi.org/10.1111/jnc.15135>.
- Kanato, Y., Ono, S., Kitajima, K., Sato, C., 2009. Complex formation of a brain-derived neurotrophic factor and glycosaminoglycans. *Biosci. Biotechnol. Biochem.* 73, 2735–2741. <https://doi.org/10.1271/bbb.90637>.
- Kandratavicius, L., Balista, P.A., Lopes-Aguiar, C., Ruggiero, R.N., Umeoka, E.H., Garcia-Cairasco, N., Bueno-Junior, L.S., Leite, J.P., 2014. Animal models of epilepsy: use and limitations. *Neuropsychiatr. Dis. Treat.* 10, 1693–1705. <https://doi.org/10.2147/NDT.S50371>.
- Karlocai, M.R., Kohus, Z., Kali, S., Ulbert, I., Szabo, G., Mate, Z., Freund, T.F., Gulyas, A. I., 2014. Physiological sharp wave-ripples and interictal events in vitro: what's the difference? *Brain* 137, 463–485. <https://doi.org/10.1093/brain/awt348>.
- Khimich, D., Nouvian, R., Pujol, R., Tom Dieck, S., Egner, A., Gundelfinger, E.D., Moser, T., 2005. Hair cell synaptic ribbons are essential for synchronous auditory signalling. *Nature* 434, 889–894. <https://doi.org/10.1038/nature03418>.
- Kraszewski, K., Mundigl, O., Daniell, L., Verderio, C., Matteoli, M., De Camilli, P., 1995. Synaptic vesicle dynamics in living cultured hippocampal neurons visualized with CY3-conjugated antibodies directed against the luminal domain of synaptotagmin. *J. Neurosci.* 15, 4328–4342. <https://doi.org/10.1523/JNEUROSCI.15-06-04328.1995>.
- Lazarevich, I., Stasenko, S., Rozhnova, M., Pankratova, E., Dityatev, A., Kazantsev, V., 2020. Activity-dependent switches between dynamic regimes of extracellular matrix expression. *PLoS ONE* 15, e0227917. <https://doi.org/10.1371/journal.pone.0227917>.
- Lesnikova, A., Casarotto, P.C., Fred, S.M., Voipio, M., Winkel, F., Steinzeig, A., Antila, H., Umemori, J., Biojone, C., Castren, E., 2021. Chondroitinase and antidepressants promote plasticity by releasing TRKB from dephosphorylating control of PTPsigma in Parvalbumin neurons. *J. Neurosci.* 41, 972–980. <https://doi.org/10.1523/JNEUROSCI.2228-20.2020>.
- Li, H., Leung, T.C., Hoffman, S., Balsamo, J., Lilien, J., 2000. Coordinate regulation of cadherin and integrin function by the chondroitin sulfate proteoglycan neurocan. *J. Cell Biol.* 149, 1275–1288. <https://doi.org/10.1083/jcb.149.6.1275>.
- Liotta, A., Caliskan, G., Ul Haq, R., Hollnagel, J.O., Rosler, A., Heinemann, U., Behrens, C.J., 2011. Partial disinhibition is required for transition of stimulus-induced sharp wave-ripple complexes into recurrent epileptiform discharges in rat hippocampal slices. *J. Neurophysiol.* 105, 172–187. <https://doi.org/10.1152/jn.00186.2010>.
- Lippmann, K., Klatf, Z.J., Salar, S., Hollnagel, J.O., Valero, M., Maslarova, A., 2022. Status epilepticus induces chronic silencing of burster and dominance of regular firing neurons during sharp wave-ripples in the mouse subiculum. *Neurobiol. Dis.* 175, 105929. <https://doi.org/10.1016/j.nbd.2022.105929>.
- Marty, S., Berzaghi Mda, P., Berninger, B., 1997. Neurotrophins and activity-dependent plasticity of cortical interneurons. *Trends Neurosci.* 20, 198–202. [https://doi.org/10.1016/S0166-2236\(96\)01026-0](https://doi.org/10.1016/S0166-2236(96)01026-0).
- McRae, P.A., Baranov, E., Rogers, S.L., Porter, B.E., 2012. Persistent decrease in multiple components of the perineuronal net following status epilepticus. *Eur. J. Neurosci.* 36, 3471–3482. <https://doi.org/10.1111/j.1460-9568.2012.08268.x>.
- McWilliam, M., Al Khalili, Y., 2023. Idiopathic (Genetic) Generalized Epilepsy. StatPearls, Treasure Island (FL). <https://pubmed.ncbi.nlm.nih.gov/31536218/>.
- Mitlöhrner, J., Kaushik, R., Niekisch, H., Blondiaux, A., Gee, C.E., Happel, M.F.K., Gundelfinger, E., Dityatev, A., Frischknecht, R., Seidenbecher, C., 2020. Dopamine receptor activation modulates the integrity of the Perisynaptic extracellular matrix at excitatory synapses. *Cells* 9, 260. <https://doi.org/10.3390/cells9020260>.
- Morelli, E., Ghiglieri, V., Pendolino, V., Bagetta, V., Pignataro, A., Fejtova, A., Costa, C., Ammassari-Teule, M., Gundelfinger, E.D., Picconi, B., Calabresi, P., 2014. Environmental enrichment restores CA1 hippocampal LTP and reduces severity of seizures in epileptic mice. *Exp. Neurol.* 261, 320–327. <https://doi.org/10.1016/j.expneurol.2014.05.010>.
- Mukhopadhyay, S., Chatterjee, A., Tiwari, P., Ghai, U., Vaidya, V.A., 2021. Postnatal fluoxetine treatment alters Perineuronal net formation and maintenance in the Hippocampus. *eNeuro* 8 (2). <https://doi.org/10.1523/ENEURO.0424-20.2021>.
- Noebels, J., 2015. Pathway-driven discovery of epilepsy genes. *Nat. Neurosci.* 18, 344–350. <https://doi.org/10.1038/nn.3933>.
- Okamoto, M., Sakiyama, J., Mori, S., Kurazono, S., Usui, S., Hasegawa, M., Oohira, A., 2003. Kainic acid-induced convulsions cause prolonged changes in the chondroitin sulfate proteoglycans neurocan and phosphacan in the limbic structures. *Exp. Neurol.* 184, 179–195. [https://doi.org/10.1016/S0014-4886\(03\)00251-6](https://doi.org/10.1016/S0014-4886(03)00251-6).
- Okerlund, N.D., Schneider, K., Leal-Ortiz, S., Montenegro-Venegas, C., Kim, S.A., Garner, L.C., Waites, C.L., Gundelfinger, E.D., Reimer, R.J., Garner, C.C., 2017. Bassoon controls presynaptic autophagy through Atg5. *Neuron* 93 (897–913), e897. <https://doi.org/10.1016/j.neuron.2017.01.026>.
- Otobe, H., Nibuya, M., Shimazaki, K., Toda, H., Suzuki, G., Nomura, S., Shimizu, K., 2014. Electroconvulsive seizures enhance autophagy signaling in rat hippocampus. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 50, 37–43. <https://doi.org/10.1016/j.pnpbp.2013.11.012>.
- Perkins, K.L., Arranz, A.M., Yamaguchi, Y., Hrabetova, S., 2017. Brain extracellular space, hyaluronan, and the prevention of epileptic seizures. *Rev. Neurosci.* 28, 869–892. <https://doi.org/10.1515/revneuro-2017-0017>.
- Perosa, S.R., Porcionatto, M.A., Cukiert, A., Martins, J.R., Amado, D., Nader, H.B., Cavalheiro, E.A., Leite, J.P., Naffah-Mazzacortti, M.G., 2002. Extracellular matrix components are altered in the hippocampus, cortex, and cerebrospinal fluid of patients with mesial temporal lobe epilepsy. *Epilepsia* 43 (Suppl. 5), 159–161. <https://doi.org/10.1046/j.1528-1157.43.s.5.30.x>.
- Perucca, P., Dubeau, F., Gotman, J., 2014. Intracranial electroencephalographic seizure-onset patterns: effect of underlying pathology. *Brain* 137, 183–196. <https://doi.org/10.1093/brain/awt299>.
- Pires, G., Leitner, D., Drummond, E., Kanshin, E., Nayak, S., Askenazi, M., Faustin, A., Friedman, D., Debure, L., Ueberheide, B., Wisniewski, T., Devinsky, O., 2021.



- Proteomic differences in the hippocampus and cortex of epilepsy brain tissue. *Brain Commun.* 3, fcab021. <https://doi.org/10.1093/braincomms/fcab021>.
- Pitkanen, A., Nodde-Ekane, X.E., Lukasiuk, K., Wilczynski, G.M., Dityatev, A., Walker, M. C., Chabrol, E., Dedeurwaerdere, S., Vazquez, N., Powell, E.M., 2014. Neural ECM and epilepsy. *Prog. Brain Res.* 214, 229–262. <https://doi.org/10.1016/B978-0-444-63486-3.00011-6>.
- Roszkowska, M., Skupien, A., Wojtowicz, T., Konopka, A., Gorlewicz, A., Kisiel, M., Bekisz, M., Ruszczycski, B., Dolezyczek, H., Rejmak, E., Knapka, E., Mozrzymas, J. W., Wlodarczyk, J., Wilczynski, G.M., Dzwonek, J., 2016. CD44: a novel synaptic cell adhesion molecule regulating structural and functional plasticity of dendritic spines. *Mol. Biol. Cell* 27, 4055–4066. <https://doi.org/10.1091/mbc.E16-06-0423>.
- Rowlands, D., Lensjo, K.K., Dinh, T., Yang, S., Andrews, M.R., Hafting, T., Fyhn, M., Fawcett, J.W., Dick, G., 2018. Aggrecan directs extracellular matrix-mediated neuronal plasticity. *J. Neurosci.* 38, 10102–10113. <https://doi.org/10.1523/JNEUROSCI.1122-18.2018>.
- Rusina, E., Bernard, C., Williamson, A., 2021. The Kainic acid models of temporal lobe epilepsy. *eNeuro* 8 (2). <https://doi.org/10.1523/ENEURO.0337-20.2021>.
- Saghatelyan, A.K., Dityatev, A., Schmidt, S., Schuster, T., Bartsch, U., Schachner, M., 2001. Reduced perisomatic inhibition, increased excitatory transmission, and impaired long-term potentiation in mice deficient for the extracellular matrix glycoprotein tenascin-R. *Mol. Cell. Neurosci.* 17, 226–240. <https://doi.org/10.1006/mcne.2000.0922>.
- Schattling, B., Engler, J.B., Volkman, C., Rothhammer, N., Woo, M.S., Petersen, M., Winkler, I., Kaufmann, M., Rosenkranz, S.C., Fejtova, A., Thomas, U., Bose, A., Bauer, S., Trager, S., Miller, K.K., Bruck, W., Duncan, K.E., Salinas, G., Soba, P., Gundelfinger, E.D., Merkler, D., Fries, M.A., 2019. Bassoon proteinopathy drives neurodegeneration in multiple sclerosis. *Nat. Neurosci.* 22, 887–896. <https://doi.org/10.1038/s41593-019-0385-4>.
- Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J.Y., White, D.J., Hartenstein, V., Eliceiri, K., Tomancak, P., Cardona, A., 2012. Fiji: an open-source platform for biological-image analysis. *Nat. Methods* 9, 676–682. <https://doi.org/10.1038/nmeth.2019>.
- Seidenbecher, C.I., Richter, K., Rauch, U., Fassler, R., Garner, C.C., Gundelfinger, E.D., 1995. Brevican, a chondroitin sulfate proteoglycan of rat brain, occurs as secreted and cell surface glycosylphosphatidylinositol-anchored isoforms. *J. Biol. Chem.* 270, 27206–27212. <https://doi.org/10.1074/jbc.270.45.27206>.
- Sgobio, C., Ghiglieri, V., Costa, C., Bagetta, V., Siliquini, S., Barone, I., Di Filippo, M., Gardoni, F., Gundelfinger, E.D., Di Luca, M., Picconi, B., Calabresi, P., 2010. Hippocampal synaptic plasticity, memory, and epilepsy: effects of long-term valproic acid treatment. *Biol. Psychiatry* 67, 567–574. <https://doi.org/10.1016/j.biopsych.2009.11.008>.
- Shao, L.R., Habela, C.W., Stafstrom, C.E., 2019. Pediatric epilepsy mechanisms: expanding the paradigm of excitation/inhibition imbalance. *Children (Basel)* 6. <https://doi.org/10.3390/children6020023>.
- Skotte, L., Fadista, J., Bybjerg-Grauholm, J., Appadurai, V., Hildebrand, M.S., Hansen, T. F., Banasik, K., Grove, J., Albinana, C., Geller, F., Bjurström, C.F., Vilhjalmsen, B.J., Coleman, M., Damiano, J.A., Burgess, R., Scheffer, I.E., Pedersen, O.B.V., Erikstrup, C., Westergaard, D., Nielsen, K.R., Sorensen, E., Bruun, M.T., Liu, X., Hjalgrim, H., Pers, T.H., Mortensen, P.B., Mors, O., Nordentoft, M., Dreier, J.W., Borglum, A.D., Christensen, J., Hougaard, D.M., Buil, A., Hviid, A., Melbye, M., Ullum, H., Berkovic, S.F., Werge, T., Feenstra, B., 2022. Genome-wide association study of febrile seizures implicates fever response and neuronal excitability genes. *Brain* 145, 555–568. <https://doi.org/10.1093/brain/awab260>.
- Soleman, S., Filippov, M.A., Dityatev, A., Fawcett, J.W., 2013. Targeting the neural extracellular matrix in neurological disorders. *Neuroscience* 253, 194–213. <https://doi.org/10.1016/j.neuroscience.2013.08.050>.
- Staley, K., 2015. Molecular mechanisms of epilepsy. *Nat. Neurosci.* 18, 367–372. <https://doi.org/10.1038/nn.3947>.
- Stamenkovic, V., Stamenkovic, S., Jaworski, T., Gawlak, M., Jovanovic, M., Jakovcevski, I., Wilczynski, G.M., Kaczmarek, L., Schachner, M., Radenovic, L., Andjus, P.R., 2017. The extracellular matrix glycoprotein tenascin-C and matrix metalloproteinases modify cerebellar structural plasticity by exposure to an enriched environment. *Brain Struct. Funct.* 222, 393–415. <https://doi.org/10.1007/s00429-016-1224-y>.
- Tom Dieck, S., Sanmarti-Vila, L., Langnaese, K., Richter, K., Kindler, S., Soyke, A., Wex, H., Smalla, K.H., Kampf, U., Franzer, J.T., Stumm, M., Garner, C.C., Gundelfinger, E.D., 1998. Bassoon, a novel zinc-finger CAG/glutamine-repeat protein selectively localized at the active zone of presynaptic nerve terminals. *J. Cell Biol.* 142, 499–509. <https://doi.org/10.1083/jcb.142.2.499>.
- Tom Dieck, S., Altmann, W.D., Kessels, M.M., Qualmann, B., Regus, H., Brauner, D., Fejtova, A., Bracko, O., Gundelfinger, E.D., Brandstatter, J.H., 2005. Molecular dissection of the photoreceptor ribbon synapse: physical interaction of bassoon and RIBEYE is essential for the assembly of the ribbon complex. *J. Cell Biol.* 168, 825–836. <https://doi.org/10.1083/jcb.200408157>.
- Valenzuela, J.C., Heise, C., Franken, G., Singh, J., Schweitzer, B., Seidenbecher, C.I., Frischknecht, R., 2014. Hyaluronan-based extracellular matrix under conditions of homeostatic plasticity. *Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci.* 369, 20130606. <https://doi.org/10.1098/rstb.2013.0606>.
- Vedunova, M., Sakharova, T., Mitroshina, E., Perminova, M., Pimashkin, A., Zakharov, Y., Dityatev, A., Mukhina, I., 2013. Seizure-like activity in hyaluronidase-treated dissociated hippocampal cultures. *Front. Cell. Neurosci.* 7, 149. <https://doi.org/10.3389/fncel.2013.00149>.
- Verhage, M., Sorensen, J.B., 2020. SNAREopathies: diversity in mechanisms and symptoms. *Neuron* 107, 22–37. <https://doi.org/10.1016/j.neuron.2020.05.036>.
- Wen, T.H., Afroz, S., Reinhard, S.M., Palacios, A.R., Tapia, K., Binder, D.K., Razak, K.A., Ethell, I.M., 2018. Genetic reduction of matrix Metalloproteinase-9 promotes formation of Perineuronal nets around Parvalbumin-expressing interneurons and normalizes auditory cortex responses in developing Fmr1 Knock-out mice. *Cereb. Cortex* 28, 3951–3964. <https://doi.org/10.1093/cercor/bhx258>.
- Wilczynski, G.M., Konopacki, F.A., Wilczek, E., Lasiecka, Z., Gorlewicz, A., Michaluk, P., Wawrzyniak, M., Malinowska, M., Okulski, P., Kolodziej, L.R., Konopka, W., Duniec, K., Mioduszewska, B., Nikolaev, E., Walczak, A., Owczarek, D., Gorecki, D. C., Zusratter, W., Ottersen, O.P., Kaczmarek, L., 2008. Important role of matrix metalloproteinase 9 in epileptogenesis. *J. Cell Biol.* 180, 1021–1035. <https://doi.org/10.1083/jcb.200708213>.
- Willis, A., Pratt, J.A., Morris, B.J., 2022. Enzymatic degradation of cortical Perineuronal nets reverses GABAergic interneuron maturation. *Mol. Neurobiol.* 59, 2874–2893. <https://doi.org/10.1007/s12035-022-02772-z>.
- Ye, T., Zhang, J., Wang, J., Lan, S., Zeng, T., Wang, H., He, X., Li, B.M., Deng, W., Liao, W.P., Liu, X.R., 2022. Variants in BSN gene associated with epilepsy with favourable outcome. *J. Med. Genet.* <https://doi.org/10.1136/jmg-2022-108865>.
- Yuan, W., Matthews, R.T., Sandy, J.D., Gottschall, P.E., 2002. Association between protease-specific proteolytic cleavage of brevicin and synaptic loss in the dentate gyrus of kainate-treated rats. *Neuroscience* 114, 1091–1101. [https://doi.org/10.1016/S0306-4522\(02\)00347-0](https://doi.org/10.1016/S0306-4522(02)00347-0).